

Summary of Financial Statements for the Fiscal Year Ended December 31, 2020

[Japanese GAAP] (Non-consolidated)

February 4, 2021

| | | |
|---|---|--|
| Company Name | Symbio Pharmaceuticals Limited | Listing: Tokyo Stock Exchange |
| Securities Code | 4582 | URL: https://www.symbiopharma.com/ |
| Representative | Representative Director, President and Chief Executive Officer | Fuminori Yoshida |
| Contact Person | Corporate Officer and Chief Financial Officer | Takaaki Fukushima TEL +81-3-5472-1125 |
| Ordinary Annual General Meeting of Shareholders | March 24, 2021 | Date of Dividend Payment (plan) — |
| Scheduled Date to File Securities Report | March 24, 2021 | |

Supplementary materials for the financial statements: Yes No Holding of earnings performance review: Yes No (For securities analysts and institutional investors)

(Amounts of less than one million yen are rounded down.)

1. Business Results for FY 2020 (January 1, 2020 to December 31, 2020)

(1) Operating Results

(Percentages indicate year-on-year changes.)

| | Net Sales | | Operating Profit (Loss) | | Ordinary Profit (Loss) | | Profit (Loss) | |
|---------|-----------------|--------|-------------------------|---|------------------------|---|-----------------|---|
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % |
| FY 2020 | 2,987 | 5.3 | (4,506) | — | (4,615) | — | (4,090) | — |
| FY 2019 | 2,837 | (26.0) | (4,301) | — | (4,376) | — | (4,376) | — |

| | Earnings (Loss) per Share | Diluted Earnings per Share | Ratio of Profit (Loss) to Equity (ROE) | Ratio of Ordinary Profit (Loss) to Total Assets (ROA) | Ratio of Operating Profit (Loss) to Net Sales |
|---------|---------------------------|----------------------------|--|---|---|
| | Yen | Yen | % | % | % |
| FY 2020 | (124.13) | — | (104.7) | (79.9) | (150.9) |
| FY 2019 | (189.03) | — | (107.4) | (76.0) | (151.6) |

(Reference) Equity in earnings of affiliates: FY 2020 — million yen

FY 2019 — million yen

(Note 1) On July 1, 2019, the Company conducted a 1-for-4 consolidation of common stock. Earnings per share have been calculated based on the assumption that this consolidation was conducted at the beginning of FY 2019.

(Note 2) Diluted earnings per share is not stated above due to recording of a net loss per share, despite the potential dilution of shares.

(2) Financial Position

| | Total Assets | Net Assets | Equity Ratio | Net Assets per Share |
|-----------------------------------|-----------------|-----------------|--------------|----------------------|
| | Millions of yen | Millions of yen | % | Yen |
| FY 2020 (as of December 31, 2020) | 6,274 | 4,657 | 64.3 | 105.76 |
| FY 2019 (as of December 31, 2019) | 5,273 | 4,400 | 71.7 | 143.07 |

(Reference) Shareholders' equity: FY 2020 (as of December 31, 2020) 4,037 million yen

FY 2019 (as of December 31, 2019) 3,779 million yen

(3) Cash Flows

| | Cash Flows from Operating Activities | Cash Flows from Investing Activities | Cash Flows from Financing Activities | Cash and Cash Equivalents at End of Period |
|---------|--------------------------------------|--------------------------------------|--------------------------------------|--|
| | Millions of yen | Millions of yen | Millions of yen | Millions of yen |
| FY 2020 | (4,122) | (160) | 4,222 | 3,848 |
| FY 2019 | (4,350) | (216) | 3,740 | 3,910 |

2. Dividends

| | Annual Dividend per Share | | | | | Total Dividends | Payout Ratio | Ratio of Dividends to Net Assets |
|--------------------|---------------------------|-------------|-------------|-----------------|-----------|-----------------|--------------|----------------------------------|
| | 1st Quarter | 2nd Quarter | 3rd Quarter | Fiscal Year End | Full Year | | | |
| | Yen | Yen | Yen | Yen | Yen | Millions of yen | % | % |
| FY 2019 | — | 0.00 | — | 0.00 | 0.00 | — | — | — |
| FY 2020 | — | 0.00 | — | 0.00 | 0.00 | — | — | — |
| FY 2021 (Forecast) | — | 0.00 | — | 0.00 | 0.00 | — | — | — |

3. Earnings Forecasts for FY 2021 (January 1, 2021 to December 31, 2021)

(Percentages indicate year-on-year changes.)

| | Net Sales | | Operating Profit (Loss) | | Ordinary Profit (Loss) | | Profit (Loss) | | Earnings (Loss) per Share |
|-----------|-----------------|-------|-------------------------|---|------------------------|---|-----------------|---|---------------------------|
| | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen |
| Full Year | 9,151 | 206.4 | 1,361 | — | 1,350 | — | 1,149 | — | 30.10 |

Notes:

(1) Changes in accounting policies, changes in accounting estimates, and restatements after error corrections

- (a) Changes in accounting policies due to revision of accounting standards: Yes • No
- (b) Changes in accounting policies due to other reasons: Yes • No
- (c) Changes in accounting estimates: Yes • No
- (d) Restatements after error corrections: Yes • No

(2) Number of issued shares (common stock)

| | | | | |
|--|---------|-------------------|---------|-------------------|
| (i) Total number of issued shares at the end of the year (including treasury shares) | FY 2020 | 38,202,956 shares | FY 2019 | 26,437,681 shares |
| (ii) Total number of treasury shares at the end of the year | FY 2020 | 30,143 shares | FY 2019 | 22,593 shares |
| (iii) Average number of shares during the year | FY 2020 | 32,950,201 shares | FY 2019 | 23,150,655 shares |

(Note) On July 1, 2019, the Company conducted a 1-for-4 consolidation of common stock. Total number of issued shares at the end of the year, total number of treasury shares at the end of the year, and average number of shares during the year have been calculated based on the assumption that this consolidation was conducted at the beginning of FY 2018.

* Summaries of financial statements are not subject to audit through certified public accountants or auditing corporations.

* Explanation regarding the appropriate use of earnings forecasts and other matters

(Notes on forward-looking statements)

All forecasts presented in this document, including earnings forecasts, are based on the information currently available to management and assumptions judged to be reasonable. Actual results may differ substantially from these forecasts due to various factors. Regarding the assumptions on which the Company's earnings forecasts are based and their usage, please refer to "1. Overview of Business Results, etc. (4) Future outlook," on Page 10 of the attachment.

Index of the attachment

| | |
|---|----|
| 1. Overview of Business Results, etc. | 4 |
| (1) Overview of business results for the fiscal year under review | 4 |
| (2) Overview of financial position for the fiscal year under review | 9 |
| (3) Overview of cash flows for the fiscal year under review | 9 |
| (4) Future outlook | 10 |
| (5) Basic policies concerning profit distribution and dividends | 10 |
| (6) Business risks | 11 |
| 2. Status of Corporate Group | 18 |
| 3. Management Policies | 18 |
| (1) Basic policy of company management | 18 |
| (2) Key performance index | 18 |
| (3) Pipeline | 19 |
| (4) Medium- to long-term strategy | 20 |
| (5) Issues to be addressed by the Company | 21 |
| (6) Other important matters concerning the Company's management | 23 |
| 4. Basic Views on Selection of Accounting Standards | 23 |
| 5. Financial Statements and Primary Notes | 24 |
| (1) Balance sheet | 24 |
| (2) Statement of income | 26 |
| (3) Statement of changes in equity | 27 |
| (4) Statement of cash flows | 29 |
| (5) Notes to going concern assumptions | 30 |
| (6) Significant accounting policies | 30 |
| (7) Notes to financial statements | 31 |
| (Balance sheet) | 31 |
| (Statement of income) | 31 |
| (Statement of changes in equity) | 33 |
| (Statement of cash flows) | 35 |
| (Financial instruments) | 36 |
| (Retirement benefits) | 39 |
| (Stock options) | 40 |
| (Asset retirement obligations) | 52 |
| (Segment information) | 53 |
| (Affiliated party information) | 54 |
| (Per share information) | 54 |
| (Significant subsequent events) | 55 |
| 6. Other | 55 |
| (1) Change in officers | 55 |
| (2) Other | 55 |

1. Overview of Business Results, etc.

(1) Overview of business results for the fiscal year under review

(Business results for the fiscal year under review)

Progress in the Company's business for the fiscal year under review is as follows.

(i) Domestic business

[Establishment of the Company's own sales organization]

With its business partnership agreement with Eisai Co., Ltd. ("Eisai") set to expire in December 2020, SymBio began preparing to establish its own sales organization for the sale of TREAKISYM® in Japan in October 2018.

In the fiscal year ended December 31, 2020 (hereafter "FY 2020"), the Company identified needs of each region and formulated detailed proposals to address these needs. In efforts to establish a salesforce with enhanced productivity, the Company assigned 53 medical representatives across the nation and nine hematology experts to each region of operation.

Further, to establish a nationwide distribution system, in September 2020 the Company concluded basic agreements with Suzuken Co., Ltd. and Toho Pharmaceutical Co., Ltd. for the distribution of pharmaceutical products, and after the partnership agreement with Eisai expired, began transactions with these two companies as its sole wholesalers. For a nationwide logistics system, the Company began collaborating with S.D. Collabo Co., Ltd and set up two logistics centers—one in Eastern and the other in Western Japan.

Through these efforts, the Company established its own sales organization, and following the expiration of its partnership agreement with Eisai, transitioned the sale of TREAKISYM® to its own sales system in December 2020.

Achieving profitability in FY 2021 and sustaining earnings growth thereafter are important issues for the Company, and with the transition to its own sales organization, its prospects for future growth have become solid.

[Stable supply of products]

SymBio imports lyophilized powder formulation of TREAKISYM® from Astellas Deutschland GmbH ("Astellas Deutschland"), a subsidiary of Astellas Pharma Inc. In the first half of FY 2020, some batches imported from Astellas Deutschland were found to contain impurities and had appearance defects, causing TREAKISYM® inventories at Eisai to trend at a lower level year-on-year. However, in the second half of the fiscal year, the Company conducted secondary packaging and quality tests for a number of imported batches, bringing the Company's inventory of the product back to its normal level.

In the fourth quarter of FY 2020, the Company obtained manufacturing and marketing approval for the ready-to-dilute (RTD) liquid formulation of TREAKISYM®, for which it entered an exclusive license agreement with Eagle Pharmaceuticals Inc. (head office: New Jersey, U.S., "Eagle"), and began importing and delivering to wholesalers the RTD formulation scheduled for market launch in January 2021.

[Anticancer agents: SyB L-0501 (lyophilized powder formulation), SyB L-1701 (ready-to-dilute ("RTD") formulation), SyB L-1702 (rapid infusion ("RI") formulation) (generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate, trade name: TREAKISYM®)]

SymBio obtained manufacturing and marketing approval for TREAKISYM® for the indications of first-line treatment of low-grade non-Hodgkin's lymphoma (low-grade NHL) ^(Note 1) and mantle cell lymphoma (MCL) in December 2016, recurrent/refractory low-grade NHL and MCL in October 2010, and chronic lymphocytic leukemia (CLL) in August 2016. TREAKISYM® is thus being used to treat a wide array of malignant lymphoma. Further, the combination therapy of TREAKISYM® and rituximab (BR therapy) was newly included in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues edited and published by the Japanese Society of Hematology in July 2018, becoming recommended as a choice for standard treatment for all previously approved indications. With this development, TREAKISYM® has established its foothold as the standard treatment for malignant lymphoma.

In July 2018, the Company obtained approval to partially revise the manufacturing and marketing authorization for TREAKISYM®, allowing the product to be used in combination with not only rituximab but also other new anti-CD20 antibodies for the treatment of CD-20 positive follicular lymphoma (FL), a typical histologic type of low-grade NHL. Having obtained approval for the partial revision, TREAKISYM® is being offered to patients as a new treatment option in combination with obinutuzumab ^(Note 2). In March 2019, the Company obtained approval to make a partial change to the authorization, allowing the use of TREAKISYM® as a pretreatment agent for tumor-specific T-cell infusion therapy ^(Note 3). This allowed TREAKISYM® to be used as a pretreatment agent for Kymriah® intravenous infusion ^(Note 4), the first chimeric antigen receptor T-cell (CAR-T)

therapy^(Note 5) to be approved in Japan. Owing to the spread of its use as a pretreatment agent for regenerative medicine and other pharmaceutical products, the status of TREAKISYM[®] as the standard treatment for malignant lymphoma has further solidified.

SymBio conducted a Phase III clinical trial of BR therapy targeting recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL), an additional indication of the combination therapy following the already-approved indications. After obtaining favorable results from the trial, with the overall response rate—the primary endpoint of the trial—exceeding expected levels, in May 2020 the Company applied for approval for a partial change to the manufacturing and marketing authorization. Further, the Company is conducting a follow-up study whose primary endpoint is overall survival, since survival data (e.g., overall survival and progression-free survival) for the BR therapy is crucial in establishing TREAKISYM[®] as a DLBCL treatment. In June 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai Pharmaceutical”) filed for manufacturing and marketing approval for polatuzumab vedotin^(Note 6) used in combination with BR therapy targeting r/r DLBCL. In response, in July 2020 the Company applied for approval to partially amend the manufacturing and marketing authorization for TREAKISYM[®] used in combination with polatuzumab vedotin and rituximab. Once polatuzumab vedotin is included in the NHI drug price list after the Company and Chugai Pharmaceutical obtain approval, TREAKISYM[®] can be used in the combination therapy of polatuzumab vedotin and BR therapy. Because currently there exists no effective treatment for r/r DLBCL, the newly added indication for TREAKISYM[®], combination therapies comprising multiple anticancer drugs are being used as rescue chemotherapy, and the development of highly effective and safe drugs is in dire need. BR therapy is already being used to treat patients with r/r DLBCL in Europe and the U.S. In Japan, patient organizations and relevant academic societies have submitted a request to the Ministry of Health, Labour and Welfare, asking to make BR therapy available as soon as possible. Once approval is granted, the Company expects TREAKISYM[®] to be widely available as a treatment option for many patients.

In September 2017, SymBio concluded a license agreement with Eagle Pharmaceuticals and obtained exclusive rights to develop and market RTD and RI liquid formulations^(Note 7) of TREAKISYM[®] in Japan. The Company obtained manufacturing and marketing approval for the RTD formulation on September 18, 2020, and launched the product in January 2021. For the RI formulation, clinical trials to confirm its safety are currently underway, and the Company plans to apply for approval in FY 2021. Unlike the current lyophilized powder formulation, RTD formulation of TREAKISYM[®] does not require the cumbersome manual work of dissolving the drug (i.e., drug reconstitution), shortening preparation time and substantially reducing burdens on healthcare providers. Further, the RI liquid formulation significantly reduces the infusion time to 10 minutes, down from the 60 minutes required by the currently available lyophilized powder and RTD formulations. This will greatly reduce burdens on patients and healthcare providers, enabling the Company to provide substantial value-added. Further, with exclusive rights to manufacture these liquid formulations, which are patent-protected, the Company is able to extend the life of these products until 2031 and further strengthen the foundation of its business growth.

- (Note 1) Non-Hodgkin’s lymphoma (NHL) refers to malignant lymphoma other than Hodgkin’s lymphoma. Malignant lymphoma is a cancer of the lymphatic system in which lymphocytes develop malignant growths. The majority of Japanese malignant lymphoma patients are suffering from NHL.
- (Note 2) Obinutuzumab (Gazyva[®], marketed by Chugai Pharmaceutical Co., Ltd.): Like rituximab recommended by treatment guidelines for non-Hodgkin’s lymphoma in Japan and overseas, obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that directly binds to CD20 (a protein expressed on B-cells other than stem cells or plasma cells) on target B-cells to attack and destroy them along with the body’s immune system.
- (Note 3) Tumor-specific T-cell infusion therapy is a treatment method in which tumor-specific T-cells (T-cells that specifically recognize cancer cells) taken from cancer patients are artificially bestowed with cancer specificity extracorporeally, amplified and then administered to the patient.
- (Note 4) Kymriah[®] intravenous infusion (generic name: tisagenlecleucel, marketed by Novartis Pharma K.K.): Kymriah[®] intravenous infusion is the first chimeric antigen receptor T-cell (CAR-T) therapy approved within Japan. Novartis Pharma received manufacturing and marketing approval for Kymriah[®] for use in the treatment of CD19 positive recurrent/refractory B-cell acute lymphoblastic leukemia (B-ALL) and CD19 positive DLBCL in March 2019. Kymriah[®] intravenous infusion was included in NHI price listings in May 2019.
- (Note 5) Chimeric antigen receptor T-cell (CAR-T) therapy is a type of tumor-specific T-cell infusion therapy that introduces genes that code chimeric antigen receptors (CARs) into T-cells, amplifies these cells and then infuses them. These chimeric antigen receptors are produced by combining the intracellular domains of T-cell receptors with the antigen binding sites of antibodies capable of recognizing membrane antigens attached to tumor cells. In clinical trials using

CARs to target CD19 that expresses on B-cells, CD19-targeting CARs were introduced into T-cells that were later administered to patients with B-cell tumors. These modified cells produced clear clinical effects.

(Note 6) Developed by Roche using Seattle Genetics' antibody-drug conjugate (ADC) technology, polatuzumab vedotin is a first-in-class anti-CD79b ADC (targeting CD79b) built by conjugating humanized monoclonal antibody targeting CD79b to a tubulin polymerization inhibitor. CD79b protein is specifically expressed on the surface of many B-cells, and is expected to be a promising target in new drug development. Polatuzumab vedotin selectively binds to CD79b while minimally affecting normal cells, and destroys B-cells with the chemotherapeutic agent it contains.

(Note 7) Ready-to-dilute (RTD) and rapid infusion (RI) are pre-dissolved liquid formulations that differ from currently available lyophilized (freeze-dried) powder injection. RTD will significantly reduce the preparation time and labor cost for healthcare providers, and RI will reduce infusion duration to 10 minutes from the current 60 minutes, providing significant benefit and value to both patients and healthcare providers.

[Anticancer agents: SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation) (generic name: rigosertib sodium)]

U.S. licensor Onconova Therapeutics, Inc. (head office: Pennsylvania, U.S., "Onconova") is conducting global Phase III clinical trials (with trial sites in more than 20 countries; INSPIRE study) of the intravenous formulation of rigosertib for higher-risk myelodysplastic syndromes (HR-MDS) which failed to respond to the current standard treatment with hypomethylating agents, relapsed after treatment under the current standard of care, or were intolerant to hypomethylating agents; the primary endpoint of the study is overall survival. In August 2020, Onconova announced that the primary endpoint—improved survival compared to physician's choice of treatment—was not met. The Company is responsible for clinical development in Japan, and is reviewing ways to use the findings from the additional analysis of the INSPIRE study in the future development of rigosertib.

As for the oral formulation of rigosertib, Onconova completed a Phase I/II clinical trial of the investigational drug (in combination with azacitidine^(Note 8)) in the U.S. in first-line HR-MDS patients, and the results suggested that the oral formulation of rigosertib and azacitidine used in combination were safe and effective. In June 2017, the Company initiated a Phase I clinical trial in Japan to confirm the safety and tolerability of high-dose monotherapy and tolerance in Japanese patients, and completed patient enrollment in June 2019.

With the aim of maximizing the business value of TREAKISYM[®] and rigosertib, the Company intends to conduct joint research with the Institute of Medical Science, the University of Tokyo, to investigate the efficacy of the drugs used in combination as well as used in combination with other existing drugs and look for new indications.

(Note 8) Azacitidine (Vidaza[®], marketed by Nippon Shinyaku Co., Ltd.): This hypomethylating agent (for injection) was approved in 2011 upon successful confirmation of extended overall survival for the first time in the Phase III clinical trial for the indication of MDS, and is currently used as a first-line drug for MDS patients who have difficulties in hematopoietic stem cell transplantation. MDS is a preleukemic state, and decrease in tumor suppressor gene due to excessive methylation of DNA is thought to be related to the disease. Hypomethylating agents such as azacitidine are thought to suppress progress to leukemia by restoring tumor suppressor gene with a deterrent effect against methylation of DNA.

[Antiviral drug: SyB V-1901 (generic name: brincidofovir)]

On September 30, 2019, the Company concluded an exclusive global licensing agreement for intravenous and oral formulation of antiviral drug brincidofovir^(Note 9) (SyB V-1901; "BCV IV" and "BCV Oral," respectively) with Chimerix Inc. (head office: North Carolina, U.S., "Chimerix"). Under this agreement, the Company acquired exclusive rights for the worldwide development, marketing, and manufacture of BCV for all human indications, excluding smallpox.

As a result of the review at the Global Advisory Board meeting convened in February 2020, the Company decided to prioritize the global development of BCV IV targeting adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation, an area with high unmet medical needs as there currently exists no effective treatment, primarily in Japan, the U.S., and Europe. Leveraging its knowledge of the efficacy and safety of BCV obtained from clinical trials, the Company plans to investigate the efficacy of BCV against a range of dsDNA^(Note 10) viral infections and expand target indications to include multiple viral infections occurring after hematopoietic stem cell transplantation. It also intends to pursue the possibility of expanding target indications of the drug to viral infections after kidney or other organ transplantation. Through these efforts, the Company aims to expand the market for BCV and maximize its business value. Currently, the Company is preparing to start clinical trials of BCV IV targeting AdV infections in children scheduled for FY 2021.

BCV Oral demonstrated highly active antiviral effects in clinical trials conducted in Europe and the U.S. by Chimerix. These trials also confirmed that BCV Oral had broad-spectrum antiviral effects. Based on these extensive antiviral effects of BCV Oral against various dsDNA viruses, the Company expects BCV IV to be also effective and safe in the treatment and prevention of various viral infections occurring after hematopoietic stem cell transplantation.

In December 2020, Chimerix announced that the U.S. Food and Drug Administration (FDA) accepted its filing of a New Drug Application (NDA) for BCV as a medical countermeasure for smallpox. The FDA granted BCV a priority review designation and based on the Prescription Drug User Fee Act (PDUFA), set the PDUFA date for April 7, 2021.

(Note 9) Brincidofovir (BCV) has a structure in which cidofovir (an antiviral drug already approved and marketed in the U.S. and Europe, but unapproved in Japan; “CDV”) is bound to a lipid chain (hexadecyloxypropyl; “HDP”). It is quickly absorbed into the lipid bilayer membrane and efficiently transferred into cells, and the bound lipid chain is metabolized and separated from the structure by intracellular phospholipases. This process generates an activator (CDV-PP; CDV diphosphate) that is retained in the cells for a long period of time, dramatically raising the compound’s antiviral activity. Furthermore, BCV avoids nephrotoxicity, a fundamental issue plaguing CDV, since HDP conjugation prevents the accumulation of the compound in renal tubular epithelial cells through organic anion transporter 1 (OAT1) and CDV is released at low levels in the bloodstream.

(Note 10) Double-stranded DNA (dsDNA) viruses include herpesviridae, adenoviridae, polyomaviridae, papillomaviridae, poxviridae families of viruses, such as CMV, AdV, HHV-6, BK virus, HSV1/2, VZV, HPV, JCV, and small pox virus.

[Patient-controlled analgesia SyB P-1501]

On October 11, 2017, Symbio initiated an arbitration against The Medicines Company (head office: New Jersey, U.S., “MDCO”)—from whom the Company in-licensed SyB P-1501 (IONSYS in the U.S.) in October 2015—under the rules of the International Chamber of Commerce, seeking damages of 82 million US dollars arising from MDCO’s decision to discontinue and withdraw IONSYS from the U.S. and European markets and failure to provide adequate assurances of MDCO’s performance under the license agreement. On September 1, 2020, the Company announced that the arbitral tribunal did not agree with the Company’s claim that MDCO failed to provide adequate assurances of performance under the license agreement and denied the Company’s claim for damages. However, the arbitral tribunal awarded the Company 4,950,000 US dollars representing 50% of its legal fees and expenses that it sought to recover in the arbitration.

(ii) Business outside Japan

SyB L-0501 is also marketed in South Korea, Taiwan, and Singapore, and product sales of SyB L-0501 in these countries were in line with the Company’s forecasts.

(iii) Licensing of new drug candidates

Symbio plans to focus on formulating and executing plans for the global development of the antiviral drug brincidofovir in-licensed in September 2019 for the time being. However, the Company will continue working on its existing initiatives of reviewing multiple licensing projects at all times and searching and evaluating new drug candidates for potential in-licensing. Through these efforts, it aims to create long-term business value as a profitable biopharmaceutical company with growth potential.

(iv) Business results

As a result of the above, net sales totaled 2,987,051 thousand yen for FY 2020, primarily reflecting product sales of TREAKISYM®, and overall net sales increased 5.3% year on year.

Selling, general and administrative expenses totaled 5,373,073 thousand yen (+4.0% year on year). This included research and development (“R&D”) expenses of 2,266,556 thousand yen (-7.2% year on year), reflecting expenses associated with clinical trials for the intravenous formulation of TREAKISYM® and the intravenous formulation of rigosertib, as well as other selling, general and administrative expenses of 3,106,517 thousand yen (+14.0% year on year), reflecting upfront spending for establishing the internal sales organization.

As a result, an operating loss of 4,506,220 thousand yen was recognized for FY 2020 (an operating loss of 4,301,615 thousand yen in the previous fiscal year). In addition, non-operating income was 2,585 thousand yen, primarily consisting of dividend income of insurance of 2,324 thousand yen. Meanwhile, non-operating expenses were 112,268 thousand yen and primarily

comprised commission expenses of 43,958 thousand yen, foreign exchange losses of 41,287 thousand yen, and share issuance cost of 27,021 thousand yen. Consequently, ordinary loss totaled 4,615,903 thousand yen (an ordinary loss of 4,376,655 thousand yen in the previous fiscal year) and bottom-line loss in FY 2020 totaled 4,090,216 thousand yen (a loss of 4,376,258 thousand yen in the previous fiscal year), partially offset by the recording of settlement received of 525,124 thousand yen.

Segment information has been omitted since the Company operates within a single segment, which includes the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities.

(2) Overview of financial position for the fiscal year under review

(Analysis of assets, liabilities, net assets, and cash flow)

Total assets as of December 31, 2020 stood at 6,274,707 thousand yen, an increase of 1,000,752 thousand yen from the previous fiscal year end. This was primarily due to decreases of 142,286 thousand yen in accounts receivable–trade, 139,715 thousand yen in software in progress, 62,203 thousand yen in cash and deposits, 41,791 thousand yen in advances paid, 21,513 thousand yen in construction in progress, and 13,357 thousand yen in prepaid expenses, which were offset by increases of 944,442 thousand yen in merchandise and finished goods, 201,031 thousand yen in software, 39,436 thousand yen in consumption taxes receivable, 14,724 thousand yen in tools, furniture and fixtures, and 10,425 thousand yen in lease and guarantee deposits. Total liabilities stood at 1,651,203 thousand yen, an increase of 777,365 thousand yen, owing mainly to increases of 578,361 thousand yen in accounts payable–trade .

Net assets amounted to 4,657,318 thousand yen, an increase of 257,201 thousand yen from the previous fiscal year end. This mainly reflected increases of 2,174,304 thousand yen in capital stock and 2,174,304 thousand yen in legal capital surplus, and a decrease of 4,090,216 thousand yen in retained earnings due to the recording of bottom-line loss. The equity ratio consequently fell by 7.3 percentage points from the previous fiscal year end, to 64.3%.

Despite a boost from the issue of new shares, cash and cash equivalents (“cash”) as of December 31, 2020 decreased of 62,203 thousand yen from the previous fiscal year end, to 3,848,626 thousand yen. This was mainly due to the recording of loss before income taxes.

(Cash flows from operating activities)

Net cash used in operating activities amounted to 4,122,483 thousand yen, compared with 4,350,738 thousand yen in cash used by these activities in the previous fiscal year. Cash inflows from operating activities mainly reflected an increase of 544,546 thousand yen in accounts payable–trade, the recording of 525,145 thousand yen in settlement package received, a decrease of 142,286 thousand yen in trade receivables, the recording of 102,378 thousand yen in share-based remuneration expenses, the recording of 63,835 thousand yen in depreciation, the recording of 43,958 thousand yen in commission expenses, a decrease of 41,791 thousand yen in advanced paid, an increase of 29,132 thousand yen in accounts payable–other, the recording of 27,021 thousand yen in share issuance cost, and a recording of 10,398 thousand yen in prepaid expenses. Cash outflows were mainly due to the recording of 4,080,416 thousand yen in loss before income taxes, an increase of 944,442 thousand yen in inventories, the recording of 525,145 thousand yen in settlement received, a payment of 41,000 thousand yen in commitment fee, and an increase of 39,436 thousand yen in consumption taxes receivable,.

(Cash flows from investing activities)

Net cash used in investing activities amounted to 160,309 thousand yen, compared with 216,462 thousand yen used in these activities in the previous fiscal year. Principal contributing factors included 133,264 thousand yen in purchase of intangible assets and 15,667 thousand yen in purchase of property, plant and equipment.

(Cash flows from financing activities)

Net cash provided by financing activities was 4,222,090 thousand yen, compared with 3,740,045 thousand yen provided by these activities in the previous fiscal year. This mainly reflected an inflow of 4,244,690 thousand yen in proceeds from issuance of shares resulting from the exercise of share acquisition rights, which offset an outflow of 27,290 thousand yen in payments for issuance of shares.

(3) Overview of cash flows for the fiscal year under review

| | 12th Term FY 2016 | 13th Term FY 2017 | 14th Term FY 2018 | 15th Term FY 2019 | 16th Term FY 2020 |
|---|----------------------|----------------------|----------------------|----------------------|----------------------|
| Equity ratio (%) | 73.5 | 63.6 | 70.1 | 71.7 | 64.3 |
| Equity ratio on a fair market value basis (%) | 165.1 | 278.4 | 250.9 | 304.0 | 230.6 |
| Debt redemption period (years) | — | — | — | — | — |
| Interest coverage ratio | — | — | — | — | — |

Equity ratio: Equity (total shareholders' equity)/total assets

Equity ratio on a fair market value basis: Total market value of common stock/total assets

Debt redemption period: Interest-bearing debt/cash flows from operating activities

Interest coverage ratio: Cash flows from operating activities/interest payments

(Notes) 1. Total market value is calculated based on the number of shares issued, excluding treasury shares.

2. Debt redemption period and interest coverage ratio are not available due to negative cash flows from operating activities.

(4) Future outlook

(i) Earnings outlook

The Company expects net sales of 9,151 million yen in FY 2021, a 206.4% increase from FY 2020, as a result of growth in sales of TREAKISYM® in Japan driven in part by the transition to its own sales organization. Meanwhile, in R&D, the Company will continue to pursue the development of TREAKISYM® for recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL); liquid formulations of TREAKISYM®; rigosertib; and antiviral drug brincidofovir in addition to the existing pipeline products.

With the aim of further enhancing enterprise value over the long term, the Company will continue to consider in-licensing new drug candidates and advance the development of its current pipeline as a whole. It has completed the construction of its own salesforce and will prepare for global business expansion to achieve profitability in FY 2021 and sustainable earnings growth thereafter. To this end, the Company anticipates R&D expenses of 2,019 million yen (2,266 million yen in FY 2020) and selling, general and administrative expenses of 5,596 million yen (5,406 million yen in FY 2020), including R&D expenses.

Key development milestones for the Company's current pipeline are as follows.

[TREAKISYM®]

For the indication of r/r DLBCL, the Company applied for approval to partially revise the manufacturing and marketing authorization of TREAKISYM® in May 2020.

In regard to the liquid formulations of TREAKISYM® in-licensed from Eagle Pharmaceuticals, the Company obtained manufacturing and marketing approval for the RTD formulation in September 2020 and launched the product in January 2021; for the RI formulation, clinical trials aimed primarily at confirming its safety are underway.

[Intravenous and oral formulation of rigosertib]

Onconova announced in August 2020 that in the global Phase III clinical trial of the intravenous formulation of rigosertib (INSPIRE study) it had been conducting, the primary endpoint—improved overall survival compared to physician's choice of treatment—was not met. The Company is in charge of clinical development in Japan, and is reviewing ways to utilize findings from the genome analysis of the INSPIRE study in the future development of rigosertib.

[Antiviral drug brincidofovir]

As a result of the review at the Global Advisory Board held in February 2020, the Company has decided to prioritize the global development of the intravenous formulation of brincidofovir (BCV IV) primarily in Japan, the U.S., and Europe targeting adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation, a niche area with a high unmet medical need. Setting our sights on global rollouts and future business expansion for BCV IV and the oral formulation of brincidofovir (BCV Oral), we will hold discussions with prominent researchers from a number of specialties and review clinical trial designs based on the knowledge we gain from these discussions.

As a result of these planned activities, the Company anticipates net sales of 9,151 million yen, an operating profit of 1,361 million yen, an ordinary profit of 1,350 million yen, and a profit of 1,149 million yen for FY 2021.

(5) Basic policies concerning profit distribution and dividends

The Company has not distributed dividends to date.

Although the Company has recorded product sales of its first product, TREAKISYM®, other pipeline products are still at the investment stage. Therefore, it is our policy to prioritize allocation of funds to strengthen our financial position and continue R&D activities rather than to distribute dividends. However, we recognize that the return of profit to shareholders is an important management issue and will continue to consider the distribution of profits based on future business performance and financial conditions.

The articles of incorporation state that the Company can pay an interim dividend, based on a corporate resolution by the Board of Directors, on June 30 every year as the record date. The Company can also distribute surplus by designating a record date in

addition to year-end and interim dividends. The decision-making body for the interim dividend is the Board of Directors, and for the year-end dividend the shareholders' meeting.

(6) Business risks

Described below are major issues that may lead to potential risks in the Company's business activities. Issues that are not necessarily considered significant by the Company are also disclosed in view of our commitment to actively provide information to investors and shareholders as these issues may carry weight in making investment decisions or in understanding our business activities. The Company is fully aware of the potential risks, and will make utmost efforts to prevent such risks from materializing, but should they occur, we intend to take appropriate action. However, we realize that investment decisions regarding our stock should be made carefully by evaluating the following matters, as well as other matters mentioned in other sections of this document. We would add that the following descriptions do not purport to cover all possible risks associated with investment in our stock. The future perspectives mentioned below reflect our understanding of our business circumstances as of the date of publication of this document.

(i) Risks associated with pharmaceutical development in general

The Company's main business is to in-license new drug candidate compounds created by pharmaceutical and bio venture companies, and to develop these into pharmaceutical products. The R&D field of pharmaceuticals is replete with strong competition, including pharmaceutical giants. In addition, specialty pharmaceutical companies, including the Company, emulate each other in quality and speed within the sector. The process from development to manufacturing and marketing involves many regulatory hurdles, necessitating a vast amount of capital input over a long period of time in business operations. Their future prospects involve uncertainty and these risk factors are associated with the Company's present and future business activities.

a) Uncertainty involved in pharmaceutical development

The pharmaceutical development process leading up to the launch of a drug generally requires a large amount of expenditure over a prolonged period. The probability of success is low. At each stage of development, it is not uncommon to make decisions on discontinuing or delaying product development. In pharmaceutical development, the different stages of development have to be conducted in phases, and at each phase a decision is made regarding whether or not development should continue. It is not unusual for a decision to be made to stop development in mid-process. The probability is low for development to progress successfully through to product launch. Even after a product is successfully developed and launched, reevaluation is conducted periodically or irregularly to confirm efficacy and safety of the product in light of academic standards in medical and pharmaceutical areas at the time of reevaluation. In cases where efficacy is not confirmed or serious side effects could lead to further damage to the health of patients, there remains a risk that approval for the product may be revoked due to concerns over efficacy and side effects (see (f): "risk associated with side effects"). To reduce and disperse these risks, the Company aims to have several drug candidates in its development pipeline and to prioritize insofar as possible the in-licensing of drug candidates with confirmed proof of concept (POC) (Note 11) in human subjects. For small specialty pharmaceutical business such as the Company, the impact of removing a single drug candidate from the development pipeline is highly material and could have a significant impact on the Company's financial position, business performance, and cash flow.

(Note 11) Proof of concept (POC) means confirming the efficacy and safety of a new drug candidate in clinical trials and verifying its practical potential.

b) Uncertainty of income

In order to generate income from the drugs in development, the Company must succeed at all stages of new drug candidate development, obtain the requisite approvals from regulatory authorities, and successfully manufacture and market the product either on our own or in partnership with a third-party. It is not assured that the Company will succeed in these activities, or even if we do succeed, we may not be able to ensure the margin of profitability needed to continue the business.

In May 2020, the Company applied for approval to partially revise the manufacture and marketing authorization for the lyophilized powder formulation of TREAKISYM[®], a pipeline product currently under development, to include as its target indication recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL). We obtained approval for the RTD liquid formulation of TREAKISYM[®] in September 2020 and launched the product in January 2021. We are also conducting clinical

trials primarily aimed at confirming the safety of the TREAKISYM® RI liquid formulation. With respect to rigosertib, Onconova announced in August 2020 that in the global Phase III clinical trial (INSPIRE study) it had been conducting, the primary endpoint—improved overall survival compared to physician’s choice of treatment—was not met. The Company is in charge of clinical development in Japan, and is reviewing ways to utilize findings from the genome analysis of the INSPIRE study to the future development of rigosertib. Furthermore, we have acquired exclusive rights for the global development, marketing, and manufacture of antiviral drug brincidofovir (BCV) for all human indications except smallpox. We have decided to prioritize the global development of the intravenous formulation of BCV (BCV IV) primarily in Japan, the U.S., and Europe targeting adenovirus (AdV) infections after hematopoietic stem cell transplantation, a niche area with a high unmet medical need.

We are promoting the development of these compounds, seeking to successfully launch the products onto the market to obtain income. In some cases, we may consider entering into an alliance with other pharmaceutical companies in development and marketing so as to expedite the inflow of income. Notwithstanding our efforts, the drug candidates in our pipeline will require a considerable amount of time under development before they reach the marketplace. There is no guarantee that they will make it onto the market as viable products, or that an alliance agreement can be signed with other pharmaceutical companies. We are of the opinion that the selection of indications and the methods of alliance and marketing identified thus far promise sufficient future profitability after considering the market size and marketing performance of approved drugs. However, should we prove to be wrong in our assessment, or should there be any change in the conditions on which the assessment is based and we fail to promptly adapt to such changes, there could be a significant impact on our financial position, business performance, and cash flow.

c) Uncertainty in legislation and regulations requiring compliance, and the health insurance system

The pharmaceutical industry, the Company’s core business, is subject to various regulatory restrictions in individual countries, which are imposed by laws and administrative guidance related to pharmaceutical drugs as well as other relevant legislation regarding all aspects of business operations (research, development, manufacturing, and marketing). We formulate our business plans in accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan and other current legislative regulations as well as the health insurance system, together with drug pricing guidelines that derive from this legislation. Notwithstanding, there is a possibility that these regulations, regulatory systems, and pricing will change before the products that we are developing reach the marketplace. If any major change does occur, there may be a significant impact on our financial position, business performance, and cash flow.

d) Risk concerning development and marketing overseas

We conduct our pharmaceutical business in Asia and other regions globally, in addition to Japan, anticipating the expansion of healthcare needs accompanying economic growth in these strategic business areas. We are formulating global business expansion plans for the future worldwide development, sale, and manufacture of antiviral drug brincidofovir, including in Asia, Europe, and the United States. In overseas markets, as in Japan, pharmaceutical development and marketing generally require very large expenditure and are associated with various business risks. To reduce investment expenditure and business risk, we out-license the development and marketing rights of some of our drug candidates to other overseas companies. Before out-licensing the rights we possess, we select a licensee after careful due diligence; we conduct monitoring when necessary after out-licensing the rights. The development and sales of out-licensed products are subject to business conditions of the licensee or any changes in the regulatory and competitive environment in respective countries, and may fall below initial expectations, resulting in lower than anticipated milestone revenue or royalty income. In such cases, there may be an impact on our financial position, business performance, and cash flow. Similarly, we regularly consider strategically utilizing partnerships with other pharmaceutical companies through methods such as joint development and sales or insourcing or outsourcing agreements. However, the Company acknowledges the possibility that actual earnings may not reach target levels if development or sales do not progress according to projections due to factors such as economic conditions at partner companies, regulations in various countries, or competitive environments. Such cases could potentially affect the Company’s financial position, business performance, and cash flow.

e) Competition in the pharmaceutical industry

The pharmaceutical industry is an intensely competitive sector. A large number of both Japanese and foreign pharmaceutical companies and research institutions, including giant multinational pharmaceuticals, compete in the arena. Technological innovation is progressing rapidly. Many competitors have a comparative advantage over the Company in terms of technology,

marketing, and financial position. Thus, these companies may more efficiently produce and sell competitor products, which are more effective than the Company's developed products. This means that what transpires in the competitive landscape with regards to development, manufacturing, and marketing operations may have a significant impact on our financial position, business performance, and cash flow.

f) Risk associated with side effects

Unexpected side effects may occur from the use of pharmaceutical products, from their clinical trial stage to post-marketing stage. If serious and unexpected side effects occur, compensation claims may be brought against the Company, or depending on the situation, there is the risk of a delay in clinical trial timelines or even discontinuation of product development. In the case where such side effects could lead to further damage to the health of patients, there is the risk of cancellation of approval or discontinuation of sales. Regarding compensation claims, the Company has in place the liability insurance necessary to minimize the financial damage should such claims arise. However, this does not exclude the possibility that the compensation awarded exceeds the amount insured. If this should occur, it could have a significant impact on the Company's financial position, business performance, and cash flow.

g) Product liability

The development and manufacturing of pharmaceutical products involves product liability risk. If in the future any products that we have developed cause damage to health or any adverse events are discovered during clinical trials, manufacturing, sales, or marketing of the drug, the Company will be subject to product liability. This may have a significant impact on the Company's financial position, business performance, and cash flow. If a product liability suit is filed against the Company, the Company's corporate image could be damaged, leading to a loss of confidence in the Company and the drugs it develops, impacting future business.

h) Risks related to manufacturing and supply stability

After bringing products under development to market, the Company must ensure a stable supply of those products. However, technological or legal issues at a business partner to whom the Company has outsourced production could interrupt or substantially delay the supply of products, as could a fire or other disaster that causes a suspension of operations. Such situations could have a significant impact on the Company's financial position, business performance, and cash flow.

(ii) Risk in business operations

a) Risk concerning the Company's business model

The Company does not own research and manufacturing facilities. Instead, the Company has adopted a business model to raise income and profit from such activities, mainly targeting orphan drugs ^(Note 12) in the areas of oncology and hematology, in-licensing drug candidates from pharmaceutical and bio venture companies with POC established through human subjects, and developing and marketing pharmaceutical products in Japan, Asia (China, Hong Kong, South Korea, Taiwan, Singapore, etc.), and other countries globally. Furthermore, we have acquired exclusive rights for the worldwide development, sale, and manufacture of antiviral drug brincidofovir (BCV) for all human indications except smallpox, through an exclusive global licensing agreement with Chimerix Inc. Utilizing these rights, we will promote our own transformation into a specialty pharmaceutical company that is capable of expanding its business into global markets and is equipped with an integrated system for supplying high-quality pharmaceutical products.

In developing and marketing the pipeline products, the Company plans to engage in alliances with other pharmaceutical companies. However, there is no guarantee that the Company can continuously in-license drug candidate compounds that satisfy in-house criteria and secure these partner companies. In addition, as the Company mainly targets orphan drugs for in-licensing ^(Note 13), it may not be able to generate expected sales turnover. Furthermore, in the event that development at a licensor is delayed or fails, there may be impact on the corresponding development in Japan. The Company also acknowledges the possibility that global business expansion may not proceed according to initial projections due to uncontrollable factors that affect the progress of development, sales, and manufacturing plans of either the Company or its corporate partners. These factors could impact the Company's financial position, business performance, and cash flow. Needless to say, intense competition within the pharmaceutical sector and changes in the Company's financial position may force the Company to revise its business model. Should this occur, there may be a significant impact on the Company's business.

(Note 12) The rare-disease field is one in which the number of patients requiring drugs is small. Drugs for this field are termed “orphan drugs.” The Japanese Ministry of Health, Labour and Welfare has established an orphan drug designation system for drugs meeting the criteria of (1) a drug to treat a serious disease that affects less than 50,000 people in Japan, and (2) for which there is a great need for medical treatment. Once designation is obtained, the drug will enjoy various advantages including shortening of the time from regulatory submission for review of the drug to approval and the extension of the re-examination period for up to 10 years.

(Note 13) “In-licensed drug candidates” are compounds or products for which obtaining the rights of development and commercialization from other companies is under consideration.

b) Dependency on specific partners and suppliers

The Company holds exclusive rights to manufacture antiviral drug brincidofovir for all human indications except for smallpox. As a specialty pharmaceutical company without production facilities, the Company currently needs to depend on the supply of products from other companies when conducting clinical trials and marketing approved drugs. Given this fact, the financial position and production conditions of the product suppliers may have a significant impact on the Company’s financial position, business performance, and cash flow. Typically, in license agreements with partner companies, revenues to be gained before the drug reaches the market include an upfront payment upon signing the contract, funding for co-development, and milestone payments. Of these, milestone payments are extremely unstable and unpredictable as they are based on the attainment of predefined results. If development progress is delayed, there may be a significant impact on the Company’s financial position, business performance, and cash flow.

c) Risk concerning intellectual property rights

During drug development activities, the Company makes use of various intellectual property rights which generally have been licensed to the Company by other companies such as pharmaceutical and bio venture companies. In relation to in-licensed drug candidates, there is a risk that patent applications by licensors relating to an out-licensed drug are not approved or are declared invalid. Moreover, it is difficult to completely avoid the possible creation of an intellectual property right by a third-party that supersedes the intellectual property right of the Company’s in-licensed drug candidate. These situations could lead to a significant impact on the Company’s financial position, business performance, and cash flow. As of the submission date of this document, no lawsuit has been filed by a third-party against the Company concerning intellectual property rights, including patents in connection with product development. When in-licensing a drug candidate, the Company will obtain advice from lawyers and conducts a thorough due diligence investigation through patent firms in order to assess such intellectual property risks. Nevertheless, it is difficult to realize full protection from the occurrence of intellectual property right disputes involving the infringement of third-party rights, and these may have a significant impact on the Company’s financial position, business performance, and cash flow. The candidate compounds that the Company in-licenses are not necessarily protected by patents. On the other hand, even if a drug candidate is not protected by a patent, the assignment of the compound for re-examination review by the regulatory authorities would restrict the entry of generic drugs during the review period, giving rise to a limited period of marketing exclusivity.

d) Information protection

To reduce the risk of significant confidential information relating to pipeline development and other business activities leaking outside the Company, the Company engages in rigorous information protection. The Company requires directors and employees, Scientific Advisory Board (SAB) members, outsourcing partners, and other business partners to sign confidentiality agreements. Even with the agreement in place, directors and employees, SAB members, outsourcing partners, and other business partners may not adhere to confidentiality, and should this occur, significant confidential information may be divulged elsewhere, which may impact the Company’s business, financial position, business performance, and cash flow.

e) Risk concerning important contracts

If any contracts that may have a significant impact on conducting the Company’s business operations are terminated due to expiration, cancellation, or for any other reason, there may be a significant impact on the Company’s financial condition, business performance, and cash flow.

(iii) Risk associated with organization

a) Risk of being a young company

SymBio is a young company founded in March 2005. Since inception, the Company has engaged in in-licensing activities of drug candidates for development. The founding President and CEO built up the pharmaceutical development business from scratch, and the Company recorded income from product sales in August 2010, for the first time in its history. There is the possibility that business issues that SymBio has never encountered arise in the future. At the moment, however, there are difficulties associated with accurately predicting any changes in the external environmental factors that may affect the Company's business results. Therefore, the Company considers business results for the past several years to be an inadequate reference to pass judgment on whether or not the Company can continue to grow.

b) Risk of being a small corporation

The Company uses contract research organizations (CROs ^(Note 14)) in conducting R&D, thereby forming a development framework requiring relatively small staff numbers. With progress in the development of the pipeline (including global expansion) already in place and with newly in-licensed drug candidates coming on line, the Company may need growth in R&D human resources. However, for whatever reason should an alliance with a CRO terminate, or should the Company fail to secure the planned number of staff, or should existing staff decide to leave, the Company's business operations may be hampered, leading to a possible impact on the Company's financial position, business performance, and cash flow.

(Note 14) A contract research organization (CRO) is an organization that provides research and other services to pharmaceutical companies, supporting pharmaceutical companies in their efforts to conduct development activities without delay. The details of the commissioned activities may include monitoring to ensure that clinical studies are carried out in full accordance with study protocols and clinical data management.

c) Dependency on a specific person

Fuminori Yoshida, the Representative Director, founding President and CEO, has played a key role since the Company's foundation in the implementation and execution of all operations in the Company's business management. Thus, in the event that he cannot continue to perform his corporate responsibilities for some unforeseen reason, this could have a significant impact on the Company's business operations.

d) Scientific Advisory Board (SAB)

The Scientific Advisory Board ("SAB") is an advisory panel to the Company's president on the potential in-licensing of new drug candidates. The Company invites members of the panel from clinicians and scientists engaged in basic research who are highly regarded in the healthcare industry due to their successful track records and wealth of experience. The SAB meets two or three times a year to engage in active discussion and debate, with each member giving his/her own perspective on an in-licensed drug candidate in the aim of building a pipeline portfolio with a balanced risk–return trade-off, while taking into consideration the degree of healthcare needs and profitability of in-licensed drug candidates, which are gathered from all over the world. The Company will continue in its efforts to acquire members of excellence for the SAB. However, if difficulty should arise in procuring members for reasons such as the cancellation, expiration, or renewal refusal of contracts with existing members, there may be an impact on the Company's ability to evaluate and in-license quality drug candidates.

(iv) Business results

a) Business performance in previous years

The Company's key business indicators are given below:

| Term | 12th Term | 13th Term | 14th Term | 15th Term | 16th Term |
|---|-------------|-------------|-------------|-------------|-------------|
| Fiscal Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
| Net sales (thousands of yen) | 2,368,112 | 3,444,206 | 3,835,530 | 2,837,753 | 2,987,051 |
| Operating profit (loss) (thousands of yen) | (2,127,049) | (3,947,061) | (2,656,072) | (4,301,615) | (4,506,220) |
| Ordinary profit (loss) (thousands of yen) | (2,316,806) | (3,976,784) | (2,748,730) | (4,376,655) | (4,615,903) |

To date, with the exception of the 4th Term, the Company's total R&D expenses and other general and administrative expenses exceeded the Company's income, resulting in the posting of an operating loss, an ordinary loss, and a bottom-line loss. For this reason, the Company does not consider the financial statements and indicators of previous years to provide

adequate reference data in making period comparisons of business performance or in forecasting future business performance.

b) Expected increase in R&D expenditures

The Company's R&D expenses for the past five fiscal years are provided below:

| Term | 12th Term | 13th Term | 14th Term | 15th Term | 16th Term |
|------------------------------------|-----------|-----------|-----------|-----------|-----------|
| Fiscal Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
| R&D expenses (thousands of yen) | 1,667,098 | 3,017,812 | 1,832,746 | 2,441,552 | 2,266,556 |

The Company intends to continue R&D activities and cumulative loss is currently trending upward. Utilizing our own salesforce, we aim to achieve profitability as a business objective in FY 2021 through expansion of product sales revenue from additional indications of TREAKISYM®. However, the achievement of this objective could potentially be hampered by a variety of factors. Through the recording of product sales revenue upon early approval for the intravenous and oral formulations of rigosertib and antiviral drug brincidofovir, and the income from alliances with pharmaceutical companies, the Company aims to collect early return on its R&D investment and continuously improve business performance as soon as possible; however, there is no guarantee that the Company will be able to achieve these aims as forecast.

c) Negative retained earnings (accumulated deficits) brought forward

SymBio is a specialty pharmaceutical company. Until products under development at the clinical stage reach the marketplace so that the Company can continuously earn stable income through product sales revenue and royalty income, the Company will continue to carry significant upfront outlay of R&D expenditure. Due to this situation, with the exception of the 4th Term, the Company has posted losses since its foundation. At the end of the 16th Term, FY 2020, the Company recorded a negative balance of 30,043,528 thousand yen as accumulated deficits brought forward. SymBio aims to become profitable at the earliest possible date by advancing its pipeline development in a rapid, precise, and efficient manner and shifting toward implementing its own internal salesforce. However, the possibility still exists that profits may not be generated in the planned timeframe. Should the Company's business fail to develop and fail to generate profits as planned, the timing of negative retained earnings brought forward becoming positive may considerably be delayed.

d) Fundraising

As a bio venture aiming to transform into a global specialty pharmaceutical company, the Company requires a large amount of funds to cover business expansion, including funds for R&D expenses. If SymBio's business plan does not take shape as planned and it suffers a shortfall in funding, the Company will endeavor to procure funds by changing strategic alliances, securing new alliance contracts, or issuing new shares. However, if the Company fails to generate funds when they are required, there may be serious doubt over the continuation of its business operations.

e) Tax losses carried forward

The Company currently has tax losses carried forward. For this reason, the Company is not subject to corporate income tax, local inhabitant tax, or enterprise tax at the standard rates and expects this to continue for several years into the future. However, if accumulated deficits are written off earlier than expected and can no longer be used as an offset to taxable income due to such reasons as the revision to current tax treatment of losses carried forward, the Company would become liable for the payments of corporate income tax, local inhabitant tax, and enterprise tax at standard rates, which may have an impact on a bottom-line profit (or loss) and cash flow currently planned.

(v) Other risks

a) Profit distribution to shareholders

Since the foundation of the Company, dividends have not been distributed. SymBio is currently at the business stage of making upfront investment for the development and commercialization (including global rollout) of pharmaceutical drugs, as well as continuous growth achieved through the application of its own internal salesforce. The Company plan to continue to prioritize using funds to strengthen its financial position, continue its R&D activities, and support in-licensing of new drug candidates. Thus, the Company has at present no plans for making dividend payouts. However, the Company recognizes that the return of profit to shareholders is an important management issue and will consider profit distribution based on future business performance and financial condition.

b) Procurement of funds

The Company may face increases in its capital requirements due to rises in necessary expenses accompanying business expansion through in-licensing of new drug candidates or unpredictable changes in external environment. Fluctuations in estimated earnings may also cause capital requirements to greatly exceed predictions in the Company forecast for the forthcoming fiscal year or in the medium- to long-term strategy. In either of these cases, the Company may obtain additional financing through means such as the issue of new shares. By doing so, the number of issued shares will increase, potentially diluting the per share value of the Company's stock.

c) Dilution of the Company's shares by the exercise of potential shares

The Company adopted a stock option plan in order to motivate and encourage higher business performance of directors and employees, and to attract human resources of excellence. In accordance with the Commercial Code of 1890 Article 280-19, 280-20, and 280-21, and the Companies Act Article 236, 238, 239, and 240, share acquisition rights are granted to directors and employees.

Additionally, the Company made a resolution at the Board of Directors meeting held on April 6, 2016 to issue the 3rd unsecured convertible bonds with share acquisition rights (total issue price: 3 billion yen) and the 39th warrant (total issue price: 9,776 thousand yen, total issue price of shares when issued through the exercise of share acquisition rights: 943,592 thousand yen) by way of third-party allotment. The Company also made a resolution at the Board of Directors meeting held on August 9, 2017 to issue the 42nd warrant (total issue price: 32,560 thousand yen, total issue price of shares when issued through the exercise of share acquisition rights: 1,892,000 thousand yen) by way of third-party allotment. Furthermore, on April 9, 2018, the Board of Directors resolved to issue the 45th through 47th warrants (total issue price: 23,100 thousand yen, total issue price of shares when issued through the exercise of share acquisition rights: 10,440,000 thousand yen) by way of third-party allotment. Further, at a Board of Directors meeting held on February 27, 2020, the Company resolved to issue the 50th and 51st warrants (total issue price: 10,540 thousand yen, total issue price of shares when issued through the exercise of share acquisition rights: 5,450,540 thousand yen) via third-party allotment, and payments for the warrants had been received as of the end of FY 2020. To attract talent, the Company may continue to offer similar incentives. This means that if these share acquisition rights are exercised in the future, per share value of the Company's stock may be diluted.

d) Stock holding by venture capitals

In general, venture capitals and investment partnerships own shares for the purpose of realizing capital gains by selling shares after IPO. If venture capitals and investment partnerships that own SymBio shares sell all or a portion of such shares, it could have an impact on the market price of the Company's shares.

e) Risk of loss on foreign exchange

The Company, which does not currently have a production facility, receives its supply of products from other companies and assumes that it will make one-off payments when in-licensing drug candidates to expand its pipeline. Suitable financing for these payments is obtained in advance through the arrangement of deposits denominated in foreign currency or foreign exchange forward contracts. Where such assets denominated in foreign currency are stated at market value in financial statements at every year end, there is a risk of loss on valuation due to foreign currency fluctuations in the future and this may have an impact on the Company's financial position, business performance, and cash flow.

f) Risk associated with natural disasters

Any disasters (earthquake, typhoon, fire, etc.) and plague that occur in the Company's geographic business domain could lead to the occurrence of human and material damage, or suspension and delay in business. In such cases, fall in social credibility and compensation issues may have an impact on the Company's financial position, business performance, and cash flow.

(VI) Risk of being delisted

The Company is expected to enter the grace period pertaining to delisting of its stock from the JASDAQ market for the following reasons: the Company had posted operating losses and negative cash flows from operating activities for the four most recent fiscal years leading up to FY 2020 (corporate performance criteria; see note below); it posted an operating loss in the fiscal year it filed its listing application; and it posted operating losses for nine consecutive fiscal years after its was listed on the market

(profits criteria). The Company is highly likely to move into the black at the operating level in FY 2021, and we will do our utmost to achieve this. However, in case operating losses persist in FY 2021 and FY 2022, the Company will be delisted from the JASDAQ market for failing to meet the market's listing criteria, if 1) the Company fails to apply to the Tokyo Stock Exchange for approval to list its stock in accordance with the initial listing criteria, or 2) the Tokyo Stock Exchange determines, upon examination, that the Company's application for listing approval does not satisfy its listing criteria.^(Note 2) If delisted, while the Company will still be able to continue its operations, executing growth strategies and maintaining business growth will become difficult due to factors including limited means of procuring funds, which in turn can significantly affect the Company's future financial position and earnings performance.

(Note) 1. The five fiscal years from the fiscal year immediately following the year the listing application was filed (FY 2012–FY 2016) are not included.

2. However, with regard to the performance criteria and profit recognition criteria established as JASDAQ's delisting criteria, the FAQ of the Listed Company Navigation System states that the same criteria are not expected to be established for the new market segment, and that JASDAQ-listed stocks that have been in the grace period due to such criteria will be removed from the grace period. For details, please refer to the FAQ of the Japan Exchange Group Listed Company Navigation System <https://faq.jpx.co.jp/disco/tse/web/knowledge7992.html>.

2. Status of Corporate Group

SymBio owns one unconsolidated subsidiary. However, its impact on financial results is insignificant, and it has therefore been omitted.

3. Management Policies

(1) Basic policy of company management

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Inc. (Note 15) (United States) and President of Amgen K.K., a wholly owned subsidiary of Amgen Inc., (now part of Takeda Pharmaceutical Company Limited) for 12 years since its establishment.

The Company aims to achieve social and management responsibilities by responding to unmet medical needs (Note 16) based on the guiding principle of mutual harmony, creating an intricate symbiotic relationship between patients, physicians, scientists, regulators, and investors.

The Company regards underserved therapeutic areas with extremely significant medical needs as a business opportunity and remains focused on the areas of oncology and hematology, where high entry barriers exist due to the high degree of specialization required. In this sense, SymBio is the first specialty pharmaceutical company in Japan. Rather than exploring opportunities to in-license and develop new “blockbuster” drugs (drugs with sales exceeding 100 billion yen), the Company channels its resources into the development of drugs in underserved markets where medical needs are high despite limited patient numbers. Holding multiple drug approvals and new drug candidates in these key therapeutic areas, the Company aims to build a solid pipeline portfolio, achieve high profitability with high-value products and services, and operate sustainable businesses.

(Note 15) Applied Molecular Genetics, or Amgen Inc., the world's largest company in the biopharmaceutical field, was founded in Thousand Oaks, California, in 1980, and started business in Japan as Amgen K.K. on May 1, 1993. After Takeda Pharmaceutical Company Limited (“Takeda”) acquired 100% of Amgen K.K.'s stock in February 2008, its operations were merged into Takeda.

(Note 16) “Unmet medical needs” means requirements for medical treatment that have not yet been fulfilled. It refers to a situation in which no effective drugs or treatments are currently available, despite strong demand by patients and/or physicians.

(2) Key performance index

As a pharmaceutical company, SymBio believes that launching new drugs onto the market on an ongoing basis through its own salesforce is an important element of securing higher enterprise value. Accordingly, we have established an integrated sales system that includes a sales organization, as well as logistics and distribution. The Company also intends to continue in-licensing drug candidates for development and aggressively investing management resources into R&D activities.

Earnings have continued to grow, mainly due to product sales, since SyB L-0501 was approved for manufacture and sale in Japan

in 2010. The Company continued collaborating with Eisai to expand sales of TREAKISYM® until our business partnership agreement expired in December 2020. From 2021, we aim to switch to our own salesforce and expand earnings further. We aim to achieve a stable and high level of profitability as soon as possible by obtaining approval for the intravenous and oral formulations of rigosertib and putting this product on the market; launching development of and commercializing antiviral drug brincidofovir in Japan and overseas; and working to in-license, promote the development of, and acquire approval for new pipeline products. We plan to refrain from setting performance index targets such as ROE or ROA until we achieve profitability on a single-year basis through the transition to our own salesforce in FY 2021.

(3) Pipeline

The Company currently has the following pipeline products under development: SyB L-0501, SyB L-1101, SyB C-1101, SyB L-1701, SyB L-1702, and SyB V-1901. The Company will continue to in-license candidate drugs to further expand and build its pipeline portfolio with a balanced risk–return trade-off.

- (i) [Anticancer agents: SyB L-0501 (lyophilized powder formulation), SyB L-1701 (RTD formulation), SyB L-1702 (RI formulation), (generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate, trade name: TREAKISYM®)]

Bendamustine hydrochloride (the generic name), the active pharmaceutical ingredient of TREAKISYM®, is an anticancer agent that has been in use for a number of years in Germany under the trade name of Ribomustin® for the treatment of non-Hodgkin’s lymphoma, multiple myeloma, and chronic lymphocytic leukemia. The Company decided to in-license this product because there is currently no effective medication for the indications of recurrent/refractory low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma. These are underserved therapeutic areas aligned with the Company’s corporate mission and also fall within one of Symbio’s targeted therapeutic fields (hematologic cancer). Astellas Deutschland GmbH, a German subsidiary of Astellas Pharma Inc., is the worldwide licensor of bendamustine hydrochloride. Cephalon, Inc. (Pennsylvania, United States), a subsidiary of Teva Pharmaceutical Industries Ltd. (Israel), in-licensed rights to bendamustine hydrochloride for North America from Astellas Pharma GmbH and obtained approvals from the U.S. Food and Drug Administration (FDA) to use the drug for the treatment of chronic lymphocytic leukemia and refractory B-cell non-Hodgkin’s lymphoma in March 2008 and October 2008, respectively. Mundipharma International Corporation Limited (United Kingdom) and Janssen-Cilag Limited (United Kingdom) are also licensed from Astellas Pharma GmbH and have obtained exclusive rights for the development and commercialization of bendamustine hydrochloride in Europe and other regions, respectively.

The Company is licensed from Astellas Deutschland GmbH with exclusive rights for the development and commercialization of bendamustine hydrochloride in Japan, China, Hong Kong, South Korea, Singapore, and Taiwan. In Japan, the drug was approved for the indications of recurrent/refractory low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma on October 27, 2010, and was launched under the trade name TREAKISYM® on December 10, 2010. In December 2015, the Company filed applications for manufacturing and marketing approval in Japan for the additional target indications of first-line treatment of low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma, and chronic lymphocytic leukemia. The Company obtained manufacturing and marketing approval for the indication of chronic lymphocytic leukemia in August 2016 and of first-line treatment of low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma in December 2016. In May 2020, the Company applied for approval to partially revise the manufacturing and marketing authorization to include the indication of recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL). In order to maximize the business value of TREAKISYM® by further promoting product life cycle management, the Company concluded an exclusive license agreement with Eagle Pharmaceuticals in September 2017 to develop, market, and sell Eagle’s ready-to-dilute (“RTD”) and rapid infusion (“RI”) liquid formulation injection products in Japan. The Company obtained approval for the RTD formulation in September 2020, and launched the product in January 2021. It is proceeding with clinical trials aimed primarily at verifying the safety of the RI formulation.

- (ii) [Anticancer agents: SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation) (generic name: rigosertib sodium)]

Rigosertib is an anticancer agent with a unique type of multikinase inhibitory activity^(Note 17). It is currently being developed in the U.S., Europe, and elsewhere by a U.S. company, Onconova Therapeutics, Inc. (“Onconova”), for the target indications of myelodysplastic syndromes (“MDS”). MDS is the pre-pathological state for malignant tumors of blood cells, which has shown increasing numbers of patients in recent years; it frequently affects elderly people; and it is a refractory disease, with a high probability of developing into leukemia.

No effective medication is available yet, especially for recurrent/refractory MDS, and it therefore constitutes an underserved therapeutic area. In July 2011, the Company signed a license agreement with Onconova, obtaining the exclusive right to develop and commercialize rigosertib in Japan and South Korea. Based on this agreement, the Company continues to develop the intravenous rigosertib formulation for the target indication of recurrent/refractory higher-risk MDS and the oral formulation for the target indication of first-line higher-risk MDS (in combination with azacitidine).

As for the intravenous formulation of rigosertib, Onconova conducted global Phase III clinical trials (INSPIRE study) with clinical trial sites in more than 20 countries worldwide, for higher-risk myelodysplastic syndromes (HR-MDS) which did not respond to the current standard treatment with hypomethylating agents, which relapsed after treatment under the current standard of care, or which were intolerant to hypomethylating agents. In August 2020, Onconova announced that the primary endpoint of the trial—improved overall survival compared to physician’s choice of treatment—was not met. The Company is in charge of clinical development in Japan, and is reviewing ways to utilize findings from the additional analysis of the INSPIRE study in the future development of rigosertib.

The oral formulation of rigosertib was shown to be effective and safe when administered in combination with azacitidine in a Phase I/II clinical trial in first-line higher-risk MDS patients conducted by Onconova in the U.S. The Company commenced a Phase I clinical trial in Japan to confirm the safety of high-dose monotherapy and tolerance in Japanese patients in Japan in June 2017, and completed patient enrollment in June 2019.

With the aim of maximizing the business value of TREAKISYM® and rigosertib, the Company intends to conduct joint research with the Institute of Medical Science, the University of Tokyo, to investigate the efficacy of the drugs used in combination as well as used in combination with other existing drugs and look for new indications.

(Note 17) Multikinase inhibitors impede the proliferation, infiltration, and metastasis of cancer cells, thereby eradicating them.

(iii) [Antiviral drug: SyB V-1901 (generic name: brincidofovir)]

On September 30, 2019, the Company concluded an exclusive global licensing agreement for antiviral drug brincidofovir (“BCV”) with Chimerix Inc. Under this agreement, the Company acquired the exclusive rights for the worldwide development, marketing, and manufacture of BCV for all human indications, excluding smallpox. With the global rights to BCV, the Company will transition into a global specialty pharmaceutical company with an integrated system for supplying high-quality pharmaceutical products.

The Company has decided to prioritize the global development of the intravenous formulation of BCV primarily in Japan, the U.S., and Europe, targeting adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation—a niche area with a high unmet medical need. We will explore all possible means of maximizing the product’s business value by applying a variety of measures, including the strategic utilization of wholly owned subsidiary Symbio Pharma USA, Inc. (established in May 2016).

(4) Medium- to long-term strategy

The Company is pursuing primarily the following five strategies in order to achieve its mid-range plan.

(i) De-risking by post-POC strategy

We in-license drug candidates for which proof of concept (POC) is already confirmed in human subjects in principle. Accordingly, they should be drugs that are in a relatively late stage of clinical development or already on the market overseas. The advanced development is already conducted overseas for these drug candidates and their efficacy and safety are already confirmed in human subjects, thereby reducing the development risk. We utilize existing clinical data available overseas so as to compress development timelines, reduce the development costs, and increase the likelihood of regulatory approvals in Japan and Asian markets.

(ii) Building a high-quality pipeline with exceptional search and evaluation capabilities

Our new drug search engine is connected to the diverse network of pharmaceutical and bio venture companies, and enables us to select promising drug candidates from the vast number of chemical compounds after the careful review by internal experts. Using their wealth of experience at the forefront of research and development, Scientific Advisory Board (SAB) members carefully evaluate and render final judgment on each drug candidate. The highly established screening process up to the final selection of drug candidates, coupled with the post-POC strategy (in which we in-license drug candidates whose efficacy and

safety are already confirmed overseas), alleviates development risk and reduces development timelines. It also helps to understand how satisfactorily the drug candidates meet the healthcare needs and to improve the accuracy of revenue projections after the product launch.

(iii) Containment of fixed costs by labless/fabless strategy

The Company does not own any research or production facilities, which are often regarded as the main cause of fixed costs. Once drug candidates are searched and in-licensed, we focus on value-added activities such as the formulation and implementation of development strategy and outsource other necessary routine procedures. This enables us to reduce development costs of pharmaceutical drugs and secure a flexible financial strategy.

(iv) Realization of high business efficiency by “Blue Ocean strategy” (Note 18)

There are many cases that the standard drug used overseas cannot be prescribed in Japan or a new drug is launched in Japan five years behind its initial approval overseas. This problem is called “drug lag” and is becoming aggravated, while the term “cancer patient refugee” has been created. This drug lag is particularly conspicuous in our strategic drug development areas of refractory cancer and hematological diseases. There is a large market of anticancer agents that continues to grow with the aging population. However, anticancer agents have a wide range of indications and they are fragmented by the type of tumor, and in some therapeutic areas there are a limited number of patients. Although an extremely high degree of specialization is required and developing new agents in these therapeutic areas is highly difficult, it is often financially unattractive for larger pharmaceutical companies to pursue due to the small size of the potential market. This is part of the cause of the delay in drugs coming to market. On the other hand, obtaining approval and launching a new drug in one of these less competitive therapeutic areas creates an opportunity to achieve superior growth and profitability by continuous indication expansion and bringing new products into the market.

(Note 18) “Blue Ocean strategy” means a strategy of redefining the market, avoiding marketplaces with fierce competition in which competitors seek to gain limited market shares (termed “red oceans”), and instead creating a “blue ocean,” an unexploited market with reduced competition, enabling profits to be maximized while providing customers with high-value products and services.

(v) Going global beyond Asia

The Company has thus far been operating its businesses in Asia centered on Japan. However, major development is unachievable if we remained in Asia, as the environment surrounding Japanese healthcare is changing drastically. Moving forward, the Company will carry out search and evaluation activities to advance new drug candidates with a view to global development. On September 30, 2019, the Company concluded an exclusive global licensing agreement for the antiviral drug brincidofovir with Chimerix Inc. (head office: North Carolina, U.S.). Under this agreement, the Company acquired the exclusive rights for the worldwide development, marketing, and manufacture of brincidofovir for all human indications, except smallpox.

(5) Issues to be addressed by the Company

The Company is committed to making improvements in the following areas.

(i) Further expansion of the pipeline

In order to enhance the enterprise value as a specialty pharmaceutical company, we need to expand the pipeline through ongoing in-licensing of new drug candidates for development.

The Company is conducting or planning development of the following anticancer agents: SyB L-0501, SyB L-1101, SyB C-1101, SyB L-1701, SyB L-1702, and antiviral drug SyB V-1901. Currently we are in discussion with counterparties regarding the in-licensing of several new drug candidates, and will continue with active efforts to in-license new drug candidates for development in order to further expand our pipeline.

(ii) Life cycle management of products in the existing pipeline

In order to enhance the enterprise value, not only in-licensing new drug candidates but also promoting product life cycle management is important. Therefore, it is critical to maximize returns from each drug under development through indication expansion after the in-licensed drugs' initial approval.

TREAKISYM® is approved for manufacturing and marketing in Japan for the indications of recurrent/refractory low-grade non-Hodgkin's lymphoma and mantle cell lymphoma, chronic lymphocytic leukemia, and first-line treatment of low-grade non-Hodgkin's lymphoma and mantle cell lymphoma. TREAKISYM® also achieved primary endpoints in the Phase III clinical trial for the target indication of recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL), and the Company applied for approval to partially revise the manufacturing and marketing authorization in May 2020 for the additional indication. In addition, the Company in-licensed RTD and RI liquid formulations of TREAKISYM® from Eagle Pharmaceuticals in efforts to maximize the business value of TREAKISYM® by promoting the product life cycle management of the product. For the RTD formulation, the Company obtained manufacturing and marketing approval in September 2020, and launched the product in January 2021. For the RI formulation, the Company is conducting clinical trials with the primary purpose of confirming the formulation's safety.

The development of intravenous and oral formulations of rigosertib for the indication of myelodysplastic syndromes (MDS) is underway. Few useful therapeutic agents are currently available for MDS, so it is an area with a very high unmet medical need. With respect to the global Phase III clinical trial (INSPIRE study) of the intravenous formulation conducted by Onconova, Onconova announced that the primary endpoint—improved overall survival compared to physician's choice of treatment—had not been met. The Company is in charge of clinical development in Japan and is reviewing ways to utilize findings from the additional analysis of the INSPIRE study in future development of rigosertib. Further, the oral formulation of rigosertib has been shown to be effective and safe when administered in combination with azacitidine in the Phase I/II clinical trial in first-line higher risk MDS patients conducted in the U.S. by Onconova. The Company commenced a Phase I clinical trial in Japan to confirm the safety of high-dose monotherapy and tolerance in Japanese patients in June 2017, and completed patient enrollment in June 2019.

With the aim of maximizing the business value of TREAKISYM® and rigosertib, the Company intends to conduct joint research with the Institute of Medical Science, the University of Tokyo, to investigate the efficacy of the drugs used in combination as well as used in combination with other existing drugs and look for new indications.

The Company has also decided to prioritize the global development of antiviral drug brincidofovir primarily in Japan, the US, and Europe targeting adenovirus infections occurring after hematopoietic stem cell transplantation, an area with a high unmet medical need. We will aim to maximize earnings through managing the lifecycle of our products as we transform into a specialty pharmaceutical company with the capacity to expand into global markets.

(iii) Preparation for the establishment of the Company's own salesforce

With the business partnership agreement with its sales agent Eisai Co., Ltd. (Eisai) set to expire in December 2020, the Company began preparing to establish its own sales organization for the domestic sales of TREAKISYM® in October 2018 and completed the process in FY 2020. Following the expiration of its business partnership agreement with Eisai, the Company transitioned the sale of TREAKISYM® to its own sales system in December 2020.

Providing specialized technical information will enable the Company to more accurately understand the needs of the market and respond more swiftly, allowing it to contribute to the benefit of patients while aiming to maximize the business value of TREAKISYM®. Furthermore, the Company strives to build a consistent sales organization with a high level of specialization in the field of hematological diseases. Through this effort, the Company aims to achieve high business efficiency, ensure sustainable earnings growth, and maximize shareholder gains once the intravenous and oral formulations of rigosertib, which are currently under development to treat myelodysplastic syndromes (MDS), join TREAKISYM® in the product lineup.

With regard to antiviral drug brincidofovir, we will not only pursue domestic sales, but also consider global business development in all parts of the world, including Europe and the United States.

(iv) Global expansion for further growth

In addition to Japan, the Company identifies China, Hong Kong, South Korea, Taiwan, and Singapore as strategic regions and has moved forward with business development in Asia.

However, with expanding medical expenditures due to the aging population in Japan, and the advent of the "era of generic drugs comprising 80% of all drugs dispensed" as a governmental policy of Japan, the business environment for innovative drug developers is expected to remain extremely challenging. Such a policy may also be implemented by other Asian countries.

Under these circumstances, the Company will promote global expansion aiming for further growth. Utilizing its experience fostered through its business in Asia, the Company will search, evaluate, and negotiate concerning new drug candidates that can follow antiviral drug brincidofovir in order to acquire their rights on a global scale.

(v) Securing personnel

The Company places the highest priority on personnel as the Company's principal management resource. Without talent, we cannot make superior achievements in terms of exploring, developing, and providing information concerning new drugs; nor can we roll out these new drugs on a global scale. We have been continually recruiting talented people; especially after being listed, we have recruited the best and brightest people in order to strengthen the management organization. Going forward, we plan to continue to further strengthen our human resources by providing on-the-job training and employee development programs.

(vi) Financial issue

It is necessary for the Company to raise funds required for business activities such as R&D expenditures as pipeline development and global business expansion progress and as drug candidates increase in number.

Therefore, we make every effort to further strengthen the financial base by continually diversifying the method of fund raising and curtailing costs through tight budget control.

(6) Other important matters concerning the Company's management

Issuance of 50th and 51st warrants

In order to secure the funds necessary for research and development, construction of its own internal salesforce, and licensing of new drug candidates, the Company made a resolution at the Board of Directors meeting held on February 27, 2020 to issue the 50th and 51st warrants (total issue price: 10,540 thousand yen, total issue price of shares when issued through the exercise of share acquisition rights: 5,450,540 thousand yen) by way of third-party allotment. The payments for the warrants had been received as of December 31, 2020.

4. Basic Views on Selection of Accounting Standards

Over the near term, the Company will prepare its financial statements based on Japanese generally accepted accounting principles (GAAP), taking into account the inter-period comparability of financial statements and comparability across companies.

In terms of the application of International Financial Reporting Standards (IFRS), the Company will take appropriate measures in light of the existing circumstances in Japan and overseas.

5. Financial Statements and Primary Notes

(1) Balance sheet

(Unit: thousands of yen)

| | FY 2019 (as of December 31, 2019) | FY 2020 (as of December 31, 2020) |
|---------------------------------------|--------------------------------------|--------------------------------------|
| Assets | | |
| Current assets | | |
| Cash and deposits | 3,910,830 | 3,848,626 |
| Accounts receivable–trade | 549,275 | 406,988 |
| Merchandise and finished goods | — | 944,442 |
| Supplies | 640 | 482 |
| Advance payments | 2,177 | 43,494 |
| Prepaid expenses | 94,002 | 80,645 |
| Advances paid | 41,791 | — |
| Consumption taxes receivable | 275,324 | 314,761 |
| Other | 13,449 | 175,852 |
| Total current assets | 4,887,491 | 5,815,292 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings | 47,486 | 59,123 |
| Accumulated depreciation | (12,751) | (16,388) |
| Buildings, net | 34,734 | 42,735 |
| Tools, furniture and fixtures | 66,241 | 90,043 |
| Accumulated depreciation | (46,998) | (56,076) |
| Tools, furniture and fixtures, net | 19,242 | 33,966 |
| Construction in progress | 21,513 | — |
| Total property, plant and equipment | 75,491 | 76,701 |
| Intangible assets | | |
| Software | 94,974 | 296,005 |
| Software in progress | 145,551 | 5,836 |
| Total intangible assets | 240,525 | 301,841 |
| Investments and other assets | | |
| Shares of subsidiaries and associates | 0 | 0 |
| Lease and guarantee deposits | 70,446 | 80,871 |
| Total investments and other assets | 70,446 | 80,871 |
| Total non-current assets | 386,463 | 459,415 |
| Total assets | 5,273,955 | 6,274,707 |
| Liabilities | | |
| Current liabilities | | |
| Accounts payable–trade | 120,913 | 665,460 |
| Unearned revenue | — | 192,705 |
| Accounts payable–other | 639,482 | 645,813 |
| Income taxes payable | 87,756 | 81,928 |
| Other | 24,066 | 29,431 |
| Total current liabilities | 872,219 | 1,615,339 |
| Non-current liabilities | | |
| Provision for retirement benefits | 1,619 | 2,050 |
| Total non-current liabilities | 1,619 | 2,050 |
| Total liabilities | 873,838 | 1,617,389 |

(Unit: thousands of yen)

| | FY 2019 (as of December 31, 2019) | FY 2020 (as of December 31, 2020) |
|-----------------------------------|--------------------------------------|--------------------------------------|
| Net assets | | |
| Shareholders' equity | | |
| Capital stock | 14,870,639 | 17,044,943 |
| Capital surplus | | |
| Legal capital surplus | 14,840,639 | 17,014,943 |
| Other capital surplus | 2,498 | 4,541 |
| Total capital surplus | 14,843,137 | 17,019,485 |
| Retained earnings | | |
| Other retained earnings | | |
| Retained earnings brought forward | (25,919,496) | (30,009,713) |
| Total retained earnings | (25,919,496) | (30,009,713) |
| Treasury shares | (15,077) | (17,538) |
| Total shareholders' equity | 3,779,202 | 4,037,177 |
| Share acquisition rights | 620,913 | 620,140 |
| Total net assets | 4,400,116 | 4,657,318 |
| Total liabilities and net assets | 5,273,955 | 6,274,707 |

(2) Statement of income

(Unit: thousands of yen)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|--|---|---|
| Net sales | | |
| Net sales of goods | 2,811,272 | 2,977,051 |
| Rights income | 26,481 | 10,000 |
| Total net sales | 2,837,753 | 2,987,051 |
| Cost of sales | | |
| Beginning merchandise inventory | 533,824 | — |
| Cost of purchased goods | 1,684,453 | 3,163,251 |
| Purchase allowance and returns | 245,276 | 98,611 |
| Total | 1,973,002 | 3,064,640 |
| Ending merchandise inventory | *1 — | *1 944,442 |
| Cost of goods sold | 1,973,002 | 2,120,198 |
| Gross profit | 864,751 | 866,853 |
| Selling, general and administrative expenses | *2 *3 5,166,366 | *2 *3 5,373,073 |
| Operating profit (loss) | (4,301,615) | (4,506,220) |
| Non-operating income | | |
| Interest income | 235 | 137 |
| Insurance claim income | 2,736 | — |
| Dividend income of insurance | 1,282 | 2,324 |
| Interest on tax refund | 76 | 120 |
| Other | 0 | 2 |
| Total non-operating income | 4,331 | 2,585 |
| Non-operating expenses | | |
| Commission expenses | 10,457 | 43,958 |
| Share issuance costs | 13,932 | 27,021 |
| Foreign exchange losses | 54,755 | 41,287 |
| Other | 227 | — |
| Total non-operating expenses | 79,372 | 112,268 |
| Ordinary profit (loss) | (4,376,655) | (4,615,903) |
| Extraordinary income | | |
| Gain on reversal of share acquisition rights | 4,197 | 4,341 |
| Settlement received | — | 525,145 |
| Total extraordinary income | 4,197 | 529,486 |
| Profit (loss) before income taxes | (4,372,458) | (4,086,416) |
| Income taxes—current | 3,800 | 3,800 |
| Total income taxes | 3,800 | 3,800 |
| Profit (loss) | (4,376,258) | (4,090,216) |

(3) Statement of changes in equity

FY 2019 (from January 1, 2019 to December 31, 2019)

(Unit: thousands of yen)

| | Shareholders' equity | | | | | | |
|---|----------------------|-----------------------|-----------------------|-----------------------|--|-------------------------|-----------------|
| | Capital stock | Capital surplus | | | Retained earnings | | Treasury shares |
| | | Legal capital surplus | Other capital surplus | Total capital surplus | Other retained earnings Retained earnings brought forward | Total retained earnings | |
| Balance at beginning of current period | 12,972,579 | 12,942,579 | — | 12,942,579 | (21,543,238) | (21,543,238) | (17) |
| Changes of items during period | | | | | | | |
| Issuance of new shares (exercise of share acquisition rights) | 1,898,059 | 1,898,059 | | 1,898,059 | | | |
| Profit (loss) | | | | | (4,376,258) | (4,376,258) | |
| Purchase of treasury shares | | | | | | | (20,871) |
| Disposal of treasury shares | | | 2,498 | 2,498 | | | 5,811 |
| Net changes of items other than shareholders' equity | | | | | | | |
| Total changes of items during period | 1,898,059 | 1,898,059 | 2,498 | 1,900,558 | (4,376,258) | (4,376,258) | (15,059) |
| Balance at end of current period | 14,870,639 | 14,840,639 | 2,498 | 14,843,137 | (25,919,496) | (25,919,496) | (15,077) |

| | Shareholders' equity | Share acquisition rights | Total net assets |
|---|----------------------------|--------------------------|------------------|
| | Total shareholders' equity | | |
| Balance at beginning of current period | 4,371,902 | 529,897 | 4,901,799 |
| Changes of items during period | | | |
| Issuance of new shares (exercise of share acquisition rights) | 3,796,119 | | 3,796,119 |
| Profit (loss) | (4,376,258) | | (4,376,258) |
| Purchase of treasury shares | (20,871) | | (20,871) |
| Disposal of treasury shares | 8,310 | | 8,310 |
| Net changes of items other than shareholders' equity | | 91,016 | 91,016 |
| Total changes of items during period | (592,699) | 91,016 | (501,683) |
| Balance at end of current period | 3,779,202 | 620,913 | 4,400,116 |

FY 2020 (from January 1, 2020 to December 31, 2020)

(Unit: thousands of yen)

| | Shareholders' equity | | | | | | |
|---|----------------------|-----------------------|-----------------------|-----------------------|-----------------------------------|-------------------------|-----------------|
| | Capital stock | Capital surplus | | | Retained earnings | | Treasury shares |
| | | Legal capital surplus | Other capital surplus | Total capital surplus | Other retained earnings | Total retained earnings | |
| | | | | | Retained earnings brought forward | | |
| Balance at beginning of current period | 14,870,639 | 14,870,639 | 2,498 | 14,843,137 | (25,919,496) | (25,919,496) | (15,077) |
| Changes of items during period | | | | | | | |
| Issuance of new shares (exercise of share acquisition rights) | 2,174,304 | 2,174,304 | | 2,174,304 | | | |
| Profit (loss) | | | | | (4,124,031) | (4,124,031) | |
| Purchase of treasury shares | | | | | | | (6,387) |
| Disposal of treasury shares | | | 2,043 | 2,043 | | | 3,926 |
| Net changes of items other than shareholders' equity | | | | | | | |
| Total changes of items during period | 2,174,304 | 2,174,304 | 2,043 | 2,176,347 | (4,124,031) | (4,124,031) | (2,461) |
| Balance at end of current period | 17,044,943 | 17,014,943 | 4,541 | 17,019,485 | (30,043,528) | (30,043,528) | (17,538) |

| | Shareholders' equity | Share acquisition rights | Total net assets |
|---|----------------------------|--------------------------|------------------|
| | Total shareholders' equity | | |
| Balance at beginning of current period | 3,779,202 | 620,913 | 4,400,116 |
| Changes of items during period | | | |
| Issuance of new shares (exercise of share acquisition rights) | 4,348,608 | | 4,348,608 |
| Profit (loss) | (4,124,031) | | (4,090,216) |
| Purchase of treasury shares | (6,387) | | (6,387) |
| Disposal of treasury shares | 5,969 | | 5,969 |
| Net changes of items other than shareholders' equity | | (772) | (772) |
| Total changes of items during period | 224,159 | (772) | 257,201 |
| Balance at end of current period | 4,003,362 | 620,140 | 4,657,318 |

(4) Statement of cash flows

(Unit: yen in thousands)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|--|---|---|
| Cash flows from operating activities | | |
| Profit (loss) before income taxes | (4,372,458) | (4,086,416) |
| Depreciation | 38,085 | 63,835 |
| Amortization of guarantee deposits | 881 | 952 |
| Share-based remuneration expenses | 127,144 | 102,378 |
| Increase (decrease) in provision for retirement benefits | 338 | 431 |
| Interest income | (235) | (137) |
| Insurance claim income | (2,736) | — |
| Settlement received | — | (525,145) |
| Foreign exchange losses (gains) | 83,370 | 1,501 |
| Commission expenses | 10,457 | 43,958 |
| Share issuance cost | 13,932 | 27,021 |
| Gain on reversal of share acquisition rights | (4,197) | (4,341) |
| Loss on retirement of non-current assets | — | 37 |
| Decrease (increase) in trade receivables | (137,554) | 142,286 |
| Decrease (increase) in inventories | 533,824 | (944,442) |
| Decrease (increase) in prepaid expenses | (18,649) | 10,398 |
| Decrease (increase) in advances paid | (10,644) | 41,791 |
| Decrease (increase) in consumption taxes refund receivable | (150,469) | (39,436) |
| Decrease (increase) in other current assets | 15,946 | (203,578) |
| Decrease (increase) in long-term prepaid expenses | 1,225 | — |
| Increase (decrease) in notes and accounts payable—trade | (605,187) | 578,361 |
| Increase (decrease) in accounts payable—other | 124,233 | 29,132 |
| Increase (decrease) in other current liabilities | 5,219 | 190,341 |
| Subtotal | (4,347,472) | (4,604,882) |
| Interest and dividends received | 235 | 153 |
| Proceeds from insurance income | 2,736 | — |
| Settlement package received | — | 525,145 |
| Commitment fee paid | (2,438) | (41,000) |
| Income taxes paid | (3,800) | (1,900) |
| Net cash provided by (used in) operating activities | (4,350,738) | (4,122,483) |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment | (24,498) | (15,667) |
| Purchase of intangible assets | (192,013) | (133,264) |
| Payments for leasehold and guarantee deposits | — | (11,377) |
| Proceeds from refund of leasehold and guarantee deposits | 50 | — |
| Net cash provided by (used in) investing activities | (216,462) | (160,309) |
| Cash flows from financing activities | | |
| Proceeds from issuance of shares resulting from exercise of share acquisition rights | 3,771,476 | 4,244,690 |
| Proceeds from issuance of share acquisition rights | — | 10,540 |
| Payments for issuance of shares | (11,582) | (27,290) |
| Purchase of treasury shares | (20,871) | (6,387) |
| Proceeds from disposal of treasury shares | 1,022 | 538 |
| Net cash provided by (used in) financing activities | 3,740,045 | 4,222,090 |
| Effect of exchange rate change on cash and cash equivalents | (83,370) | (1,501) |
| Net increase (decrease) in cash and cash equivalents | (910,525) | (62,203) |
| Cash and cash equivalents at beginning of period | 4,821,355 | 3,910,830 |

(Unit: yen in thousands)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|--|---|---|
| Cash and cash equivalents at end of period | *1 3,910,830 | *1 3,848,626 |

(5) Notes to going concern assumptions

None to be reported.

(6) Significant accounting policies

1. Valuation basis and method of marketable and investment securities

(1) Shares of subsidiaries and associates

Shares of subsidiaries and associates are stated at cost determined by the moving-average method.

(2) Other marketable and investment securities

Available-for-sale securities with determinable market value

Available-for-sale securities with a determinable market value are stated at fair value based on marketable value on the closing date and other premises. Any valuation differences are included directly in shareholders' equity. Cost of securities sold is calculated by the moving-average method.

Available-for-sale securities without determinable market value

Available-for-sale securities without determinable market value are stated at cost determined by the moving-average method.

2. Valuation basis and method of derivative transactions

Derivative financial instruments are stated at fair value.

3. Valuation basis and method of inventories

Inventories are stated at cost determined by the weighted-average method. The amount on the balance sheet is calculated by reducing book value when the contribution of inventories to profitability declines.

4. Depreciation and amortization of non-current assets

(1) Property, plant and equipment (excluding lease assets)

Depreciation of property, plant and equipment is computed by the straight-line method.

The useful lives of major property, plant and equipment are summarized as follows:

Buildings 3 to 18 years

Tools, furniture and fixtures 4 to 20 years

(2) Intangible assets (excluding lease assets)

Amortization of intangible assets is computed by the straight-line method.

Capitalized software costs are being amortized over the period of the internal use of five years.

(3) Lease assets

Depreciation of lease assets is computed by the straight-line method over the lease term with no residual value.

5. Deferred assets

Share issuance costs and bond issuance costs are recorded as expenses in full at the time of expenditure.

6. Basis for translating assets and liabilities denominated in foreign currencies into Japanese yen

Monetary assets and liabilities denominated in foreign currencies are translated into yen at the spot exchange rates prevailing on the closing date, and resulting gains or losses are credited or charged to income.

7. Basis for reserves and provisions

(1) Allowance for doubtful accounts

The allowance for doubtful accounts is provided at an amount determined based on the historical experience of bad debt with respect to ordinary receivables and an estimate of uncollectible amounts determined by reference to specific doubtful receivables from customers which are experiencing financial difficulties.

For the fiscal year under review, no allowance for doubtful accounts is provided due to no historical experience of bad debt and no receivable balances that are deemed uncollectible.

(2) Provision for retirement benefits

The provision for retirement benefits is provided based on an estimated amount for retirement benefit obligations as of the end of the fiscal year under review.

The Company applies the simplified method to calculate amounts of provision for retirement benefits and retirement benefit expenses. That is, the amount of retirement benefit obligations are the payments required for voluntary retirement as of each fiscal year end.

8. Cash and cash equivalents in the statement of cash flows

Cash and cash equivalents consist of cash on hand, cash in banks which can be withdrawn at any time, and short-term investments with a maturity of three months or less that can easily be converted to cash and are subject to little risk of change in value.

9. Other significant basis for the preparation of financial statements

Accounting for consumption tax

Transactions are recorded at amounts exclusive of consumption tax.

(7) Notes to financial statements

(Balance sheet)

The Company has overdraft and commitment line contracts with three banks in a business relationship to efficiently procure working capital. The status of the bank overdraft and loan commitments based on these contracts at the end of each fiscal year is as follows:

| | (Unit: thousands of yen) | |
|--|--------------------------------------|--------------------------------------|
| | FY 2019 (as of December 31, 2019) | FY 2020 (as of December 31, 2020) |
| Total amounts of bank overdraft limit and loan commitment line | 1,350,000 | 3,150,000 |
| Balance of borrowing outstanding | — | — |
| Unused balance | 1,350,000 | 3,150,000 |

(Statement of income)

* 1 Inventories at fiscal year-end are stated after writing down based on the decrease in profitability. The following amount is included within cost of sales as loss on valuation of inventories.

| | (Unit: thousands of yen) | |
|--|---|---|
| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
| | 187,840 ^(Note) | 69,199 ^(Note) |

(Note) A batch of TREAKISYM® 100 mg was determined to be unsalable due to quality issues, resulting in an inventory valuation loss.

* 2 The selling expenses ratio is roughly 14.2% and 24.0% for FY 2019 and FY 2020 respectively, and the general and administrative expenses ratio is roughly 85.8% and 76.0% for FY 2019 and FY 2020, respectively.

Major expense items and amounts are as follows:

(Unit: thousands of yen)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|---|---|---|
| Remuneration for directors (and other officers) | 166,833 | 119,105 |
| Salaries and allowance | 338,543 | 410,547 |
| Retirement benefit expenses | 555 | 753 |
| Research and development expenses | 2,441,552 | 2,266,556 |
| Depreciation | 19,362 | 40,171 |
| Fee expenses | 711,781 | 405,325 |
| Promotion expenses | 733,688 | 1,301,048 |

* 3 Total amounts of research and development expenses included in general and administrative expenses
(Unit: thousands of yen)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|--|---|---|
| | 2,441,552 | 2,266,556 |

(Statement of changes in equity)

FY 2019 (from January 1, 2019 to December 31, 2019)

1. Type and number of shares issued and treasury shares

(Unit: number of shares)

| | At beginning of current period | Increase | Decrease | At end of current period |
|-----------------|--------------------------------|------------|------------|--------------------------|
| Shares issued | | | | |
| Common stock | 82,398,924 | 17,126,800 | 73,088,043 | 26,437,681 |
| Total | 82,398,924 | 17,126,800 | 73,088,043 | 26,437,681 |
| Treasury shares | | | | |
| Common stock | 75 | 31,050 | 8,532 | 22,593 |
| Total | 75 | 31,050 | 8,532 | 22,593 |

- (Notes)
1. Increase of 17,126,800 issued shares of common stock is due to the exercise of share acquisition rights.
 2. Decrease of 73,088,043 issued shares of common stock is due to the 1-for-4 consolidation of common stock conducted on July 1, 2019.
 3. Increase of 31,050 issued shares of common stock is due to the purchase of fractional shares.
 4. Of the decrease of 8,532 common treasury shares, 57 were due to the 1-for-4 consolidation of common stock conducted on July 1, 2019, 6,775 were due to exercise of share acquisition rights, and 1,700 were sold to owners of fractional shares.

2. Share acquisition rights

| Company | Description | Type of shares to be issued | Number of shares to be issued | | | | Balance as of December 31, 2018 (thousands of yen) |
|--------------------------------|---|-----------------------------|--------------------------------|----------|------------|--------------------------|--|
| | | | At beginning of current period | Increase | Decrease | At end of current period | |
| SymBio Pharmaceuticals Limited | The 46th warrant | Common stock | 15,000,000 | — | 15,000,000 | — | — |
| | The 47th warrant | Common stock | 15,000,000 | — | 13,325,000 | 1,675,000 | 2,546 |
| | Share acquisition rights as stock options | — | — | — | — | — | 618,367 |
| Total | | | 30,000,000 | — | 28,325,000 | 1,675,000 | 620,913 |

(Note) The information about the type and number of shares to be issued pertaining to share acquisition rights as stock options is described in “Stock options.”

(Main reasons for increase/decrease)

Decrease due to exercise of the 46th warrant: 15,000,000 shares

Decrease due to the 1-for-4 consolidation of the common shares of the 47th warrant conducted on July 1, 2019: 11,250,000 shares

Decrease due to exercise of the 47th warrant: 2,075,000 shares

3. Dividends

None to be reported.

FY 2020 (from January 1, 2020 to December 31, 2020)

1. Type and number of shares issued and treasury shares

(Unit: number of shares)

| | At beginning of current period | Increase | Decrease | At end of current period |
|-----------------|--------------------------------|------------|----------|--------------------------|
| Shares issued | | | | |
| Common stock | 26,437,681 | 11,765,275 | — | 38,202,956 |
| Total | 26,437,681 | 11,765,275 | — | 38,202,956 |
| Treasury shares | | | | |
| Common stock | 22,593 | 13,900 | 6,350 | 30,143 |
| Total | 22,593 | 13,900 | 6,350 | 30,143 |

(Notes) 1. Increase of 11,765,275 issued shares of common stock is due to the exercise of share acquisition rights.
 2. Increase of 13,900 issued shares of common stock is due to the purchase of fractional shares.
 3. Of the decrease of 6,350 common treasury shares, 5,200 were due to exercise of share acquisition rights, and 1,150 were sold to owners of fractional shares.

2. Share acquisition rights

| Company | Description | Type of shares to be issued | Number of shares to be issued | | | | Balance as of December 31, 2018 (thousands of yen) |
|--------------------------------|---|-----------------------------|--------------------------------|------------|------------|--------------------------|--|
| | | | At beginning of current period | Increase | Decrease | At end of current period | |
| SymBio Pharmaceuticals Limited | The 47th warrant | Common stock | 1,675,000 | — | 1,675,000 | — | — |
| | The 50th warrant | Common stock | — | 7,000,000 | 7,000,000 | — | — |
| | The 51st warrant | Common stock | — | 3,000,000 | 3,000,000 | — | — |
| | Share acquisition rights as stock options | — | — | — | — | — | 620,140 |
| Total | | | 1,675,000 | 10,000,000 | 11,675,000 | — | 620,140 |

(Note) The information about the type and number of shares to be issued pertaining to share acquisition rights as stock options is described in “Stock options.”

(Main reasons for increase/decrease)

Decrease due to exercise of the 47th warrant: 1,675,000 shares

Increase due to issuance of the 50th warrant: 7,000,000 shares

Decrease due to exercise of the 50th warrant: 7,000,000 shares

Increase due to issuance of the 51st warrant: 3,000,000 shares

Decrease due to exercise of the 51st warrant: 3,000,000 shares

3. Dividends

None to be reported.

(Statement of cash flows)

*1. Cash and cash equivalents as of the fiscal year end are reconciled to the accounts reported in the balance sheet as follows:

| | (Unit: thousands of yen) | |
|---------------------------|---|---|
| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
| Cash and deposits | 3,910,830 | 3,848,626 |
| Cash and cash equivalents | 3,910,830 | 3,848,626 |

(Financial instruments)

1. Financial instruments

(1) Policies for financial instruments

The Company procures the funds necessary in light of the pipeline development plan (primarily by third-party allotment and offering by new share issuance). A temporary surplus fund is invested in financial instruments which are highly safe and liquid.

As a principle, the Company does not enter into derivative transactions for speculative trading purposes but uses them within the scope prescribed in the Company's internal rules.

(2) Types of financial instruments and related risks

Operating receivables such as accounts receivable—trade and advances paid in connection with joint development are exposed to the credit risk of customers and joint development partners. Operating receivables denominated in foreign currencies are exposed to foreign exchange fluctuation risk.

The Company intends to invest in marketable and investment securities which have a relatively low risk of falling below initial investments, however, it might entail a finite risk.

Operating payables such as accounts payable—trade and accounts payable—other are mostly due within 75 days. Operating payables denominated in foreign currencies are exposed to foreign exchange fluctuation risk.

The Company uses derivative transactions to avoid foreign exchange fluctuation risks and enters into forward exchange contracts within the scope prescribed in the internal rules based on balances of receivables and payables denominated in foreign currencies as well as the actual volume of export and import transactions denominated in foreign currencies.

Lease and guarantee deposits are mostly security deposits related to leased office premises and their refunds are subject to the credit risk of the lessor.

(3) Risk management for financial instruments

(i) Monitoring of credit risks (the risk that customers or counterparties may default on obligations)

In accordance with the Company's internal credit policies for managing credit risk arising from operating receivables, the Company's marketing department periodically monitors the creditworthiness of major customers and monitors due dates and outstanding balances by individual customers. In addition, the Company is making efforts to promptly identify and mitigate risks of bad debts from customers who are having financial difficulties.

The Company enters into derivative transactions only with financial institutions which have a sound credit profile in order to mitigate the counterparty risk.

(ii) Monitoring of market risk (the risk arising from fluctuations in foreign exchange rates, interest rates, and others)

The Company deposits cash primarily with financial institutions with high credit ratings.

For marketable and investment securities, the Company intends to avoid risks of falling below initial investments by investing in securities with a satisfactory credit rating and investment period in accordance with the Company's internal investment policies.

The Company enters into forward exchange contracts in order to avoid foreign exchange fluctuation risks in connection with receivables and payables denominated in foreign currencies.

Followed by appropriate authorization procedures prescribed in the Company's internal rules, the Finance & Accounting department executes and monitors derivative transactions. Monthly transaction performances are reported to the executive management committee.

(iii) Monitoring of liquidity risks (the risk that the Company may not be able to meet its obligations on the scheduled due date)

Based on the report from each department, the responsible department of the Company prepares and updates its cash flow plans on a timely basis and ensures to maintain the liquidity on hand to manage liquidity risk.

(4) Supplementary explanation of the estimated fair value of financial instruments

The fair value of financial instruments is based on their quoted market price, if available. When there is no quoted market price available, fair value is reasonably estimated. Since various assumptions and factors are reflected in

estimating the fair value, different assumptions and factors could result in different fair value. In addition, the notional amounts of derivatives in notes to “Derivative transactions” are not necessarily indicative of the actual market risk involved in derivative transactions.

(5) Concentration of credit risk

As of the end of the fiscal year under review, 100% of operating receivables are from one particular major customer.

2. Fair value of financial instruments

The carrying value on the balance sheet, fair values, and their differences are as follows. The financial instruments whose fair value is extremely difficult to determine are not included. (See Note 2.)

FY 2019 (as of December 31, 2019)

(Unit: thousands of yen)

| | Carrying value on the balance sheet | Fair value | Differences |
|------------------------------------|-------------------------------------|------------|-------------|
| (1) Cash and deposits | 3,910,830 | 3,910,830 | — |
| (2) Accounts receivable—trade | 549,275 | 549,275 | — |
| (3) Advances paid | 41,791 | 41,791 | — |
| (4) Consumption taxes receivable | 275,324 | 275,324 | — |
| Assets, total | 4,777,222 | 4,777,222 | — |
| (1) Accounts payable—trade | 120,913 | 120,913 | — |
| (2) Accounts payable—other | 639,482 | 639,482 | — |
| (3) Income taxes payable | 87,756 | 87,756 | — |
| Liabilities, total | 848,153 | 848,153 | — |
| Derivative transactions, total (*) | — | — | — |

(*) Receivables and liabilities arising from derivative transactions are presented on a net basis and net liabilities are shown in parentheses.

FY 2020 (as of December 31, 2020)

(Unit: thousands of yen)

| | Carrying value on the balance sheet | Fair value | Differences |
|------------------------------------|-------------------------------------|------------|-------------|
| (1) Cash and deposits | 3,848,626 | 3,848,626 | — |
| (2) Accounts receivable—trade | 406,988 | 406,988 | — |
| (3) Advances paid | — | — | — |
| (4) Consumption taxes receivable | 314,761 | 314,761 | — |
| Assets, total | 4,570,376 | 4,570,376 | — |
| (1) Accounts payable—trade | 699,274 | 699,274 | — |
| (2) Accounts payable—other | 645,813 | 645,813 | — |
| (3) Income taxes payable | 81,928 | 81,928 | — |
| Liabilities, total | 1,427,016 | 1,427,016 | — |
| Derivative transactions, total (*) | — | — | — |

(*) Receivables and liabilities arising from derivative transactions are presented on a net basis and net liabilities are shown in parentheses.

(Notes)

1. Fair value measurement of financial instruments and other matters related to securities and derivative transactions

Assets

(1) Cash and deposits, (2) Accounts receivable—trade, (3) Advances paid, and (4) Consumption taxes receivable

The carrying value is deemed as the fair value since these are scheduled to be settled in a short period of time.

Liabilities

(1) Accounts payable–trade, (2) Accounts payable–other, and (3) Income taxes payable

The carrying value is deemed as the fair value since these are scheduled to be settled in a short period of time.

Derivative transactions

See notes to “Derivative transactions.”

2. Financial instruments whose fair value is extremely difficult to determine

(Unit: thousands of yen)

| | FY 2019 (as of December 31, 2019) | FY 2020 (as of December 31, 2020) |
|------------------------------|--------------------------------------|--------------------------------------|
| Lease and guarantee deposits | 70,446 | 80,871 |

Lease and guarantee deposits are not included in the above table since no market quote is available and their fair value is extremely difficult to determine.

3. The redemption schedule for monetary assets and securities with maturities after the closing date

FY 2019 (as of December 31, 2019)

(Unit: thousands of yen)

| | Due in one year or less | Due after one year through five years | Due after five years through ten years | Due after ten years |
|------------------------------|-------------------------|---------------------------------------|--|---------------------|
| Deposits | 3,910,739 | — | — | — |
| Accounts receivable–trade | 549,275 | — | — | — |
| Advances paid | 41,791 | — | — | — |
| Consumption taxes receivable | 275,324 | — | — | — |
| Total | 4,777,131 | — | — | — |

FY 2020 (as of December 31, 2020)

(Unit: thousands of yen)

| | Due in one year or less | Due after one year through five years | Due after five years through ten years | Due after ten years |
|------------------------------|-------------------------|---------------------------------------|--|---------------------|
| Deposits | 3,848,535 | — | — | — |
| Accounts receivable–trade | 406,988 | — | — | — |
| Advances paid | — | — | — | — |
| Consumption taxes receivable | 314,761 | — | — | — |
| Total | 4,570,285 | — | — | — |

(Retirement benefits)

1. Outline of retirement benefit plans

The Company has adopted a defined contribution pension plan. A lump-sum payment plan (non-contributory plan) is applied for certain employees based on the Company's internal rules for retirement benefits.

The simplified method is applied to calculate amounts of provision for retirement benefits and retirement benefit expenses.

2. Retirement benefit plan under the simplified method

(1) The reconciliation of provision for retirement benefits at the beginning and the end of the fiscal year under the simplified method is as follows:

| | (Unit: thousands of yen) | |
|--|---|---|
| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
| Provision for retirement benefits at beginning of period | 1,281 | 1,619 |
| Retirement benefit expenses | 431 | 530 |
| Paid amount of retirement benefits | (93) | (99) |
| Provision for retirement benefits at end of period | 1,619 | 2,050 |

(2) The reconciliation of retirement benefit obligations or pension assets at the end of the fiscal year and provision for retirement benefits and the prepaid pension cost on the balance sheet is as follows:

| | (Unit: thousands of yen) | |
|---|--------------------------------------|--------------------------------------|
| | FY 2019 (as of December 31, 2019) | FY 2020 (as of December 31, 2020) |
| Retirement benefit obligations under non-contributory plan | 1,619 | 2,050 |
| Net defined benefit liability or asset on the balance sheet | 1,619 | 2,050 |
| Provision for retirement benefits | 1,619 | 2,050 |
| Net defined benefit liability or asset on the balance sheet | 1,619 | 2,050 |

(3) Retirement benefit expenses

Retirement benefit expenses calculated under the simplified method FY 2019: 431 thousand yen
FY 2020: 530 thousand yen

3. Defined contribution pension plan

The amount of the Company's contribution to the defined contribution pension plan for FY 2019 and FY 2020 were 1,024 thousand yen and 3,048 thousand yen, respectively.

(Stock options)

1. The account title and the amount of stock options charged as expenses

(Unit: thousands of yen)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|--|---|---|
| Selling, general and administrative expenses | 127,144 | 102,378 |

2. The account title and the amount of income recognized for vested shares that expired unexercised

(Unit: thousands of yen)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|--|---|---|
| Gain on reversal of share acquisition rights | 4,197 | 4,341 |

3. Description of stock options and changes in the size of stock options

The following information is based on stock options that were available in the fiscal year ended December 31, 2020.

The number of stock options is converted into the number of shares.

On July 1, 2019, we conducted a 1-for-4 consolidation of common stock, and figures below reflect its impact.

(1) Description of stock options

| | The 20th Warrant | The 21st Warrant |
|--|---|--------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 6 Audit & Supervisory Board member of the Company 1 Total 7 | Employees of the Company 50 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 90,250 shares | Common stock 81,625 shares |
| Grant date | March 31, 2010 | March 31, 2010 |
| Vesting conditions | 1. The Person Granted must have the status as the Company's director, Audit & Supervisory Board member, advisor, or employee at the time of exercise. However, this is not necessarily the case if the Person Granted retires due to the expiry of her/his term or compulsory retirement; if otherwise the Board of Directors approves; or if the Person Granted is an external collaborator. 2. The Company's stock must be listed on a stock exchange. | Same as on the left |
| Vesting period | The vesting period is not fixed. | Same as on the left |
| Exercise period | From April 1, 2012 to March 31, 2020 | From April 1, 2012 to March 31, 2020 |

| | The 22nd Warrant | The 23rd Warrant |
|--|---|---|
| Individuals covered by the plan and number of persons granted stock options | External collaborators 13 | Employees of the Company 9 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 38,250 shares | Common stock 8,000 shares |
| Grant date | March 31, 2010 | October 15, 2010 |
| Vesting conditions | 1. The Person Granted must have the status as the Company's director, Audit & Supervisory Board member, advisor, or employee at the time of exercise. However, this is not necessarily the case if the Person Granted retires due to the expiry of her/his term or compulsory retirement; if otherwise the Board of Directors approves; or if the Person Granted is an external collaborator. 2. The Company's stock must be listed on a stock exchange. | Same as on the left |
| Vesting period | The vesting period is not fixed. | Same as on the left |
| Exercise period | From April 1, 2012 to March 31, 2020 | From October 15, 2012 to October 14, 2020 |

| | The 24th Warrant | The 25th Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 5 | Employees of the Company 59 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 48,000 shares | Common stock 48,750 shares |
| Grant date | March 31, 2011 | March 31, 2011 |
| Vesting conditions | <p>1. The Person Granted must have the status as the Company's director, Audit & Supervisory Board member, advisor, or employee at the time of exercise. However, this is not necessarily the case if the Person Granted retires due to the expiry of her/his term or compulsory retirement; or if otherwise the Board of Directors approves or if the Person Granted is an external collaborator.</p> <p>2. The Company's stock must be listed on a stock exchange.</p> | Same as on the left |
| Vesting period | The vesting period is not fixed. | Same as on the left |
| Exercise period | From March 31, 2013 to March 30, 2021 | From March 31, 2013 to March 30, 2021 |

| | The 26th Warrant | The 27th Warrant |
|--|---|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 4 | Employees of the Company 70 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 90,625 shares | Common stock 107,675 shares |
| Grant date | May 2, 2012 | May 2, 2012 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1) to (6). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise conditions *(2) and (5). | Same as on the left |
| Exercise period | From April 18, 2014 to April 17, 2022 | From April 18, 2014 to April 17, 2022 |

| | The 30th Warrant | The 31st Warrant |
|--|---|-----------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 5 | Employees of the Company 68 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 29,000 shares | Common stock 31,000 shares |
| Grant date | May 29, 2013 | May 29, 2013 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1) to (6). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise conditions *(2) and (5). | Same as on the left |
| Exercise period | From May 15, 2015 to May 14, 2023 | From May 15, 2015 to May 14, 2023 |

| | The 32nd Warrant | The 33rd Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 5 | Employees of the Company 68 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 63,000 shares | Common stock 82,500 shares |
| Grant date | April 30, 2014 | April 30, 2014 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From April 16, 2017 to April 15, 2024 | From April 16, 2017 to April 15, 2024 |

| | The 35th Warrant | The 36th Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 6 | Employees of the Company 61 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 51,050 shares | Common stock 78,000 shares |
| Grant date | April 10, 2015 | April 10, 2015 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From March 27, 2018 to March 26, 2025 | From March 27, 2018 to March 26, 2025 |

| | The 37th Warrant | The 38th Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 6 | Employees of the Company 73 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 59,125 shares | Common stock 98,750 shares |
| Grant date | April 14, 2016 | April 14, 2016 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From March 31, 2019 to March 30, 2026 | From March 31, 2019 to March 30, 2026 |

| | The 40th Warrant | The 41st Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 6 | Employees of the Company 71 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 70,000 shares | Common stock 112,800 shares |
| Grant date | April 24, 2017 | April 24, 2017 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From March 30, 2020 to March 29, 2027 | From March 30, 2020 to March 29, 2027 |

| | The 43rd Warrant | The 44th Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 6 | Employees of the Company 74 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 76,250 shares | Common stock 116,200 shares |
| Grant date | April 26, 2018 | April 26, 2018 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From March 30, 2021 to March 29, 2028 | From March 30, 2021 to March 29, 2028 |

| | The 48th Warrant | The 49th Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 6 | Employees of the Company 92 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 78,750 shares | Common stock 179,125 shares |
| Grant date | April 22, 2019 | April 22, 2019 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From March 30, 2022 to March 29, 2029 | From March 30, 2022 to March 29, 2029 |

| | The 52th Warrant | The 53rd Warrant |
|--|--|---------------------------------------|
| Individuals covered by the plan and number of persons granted stock options | Directors of the Company 4 | Employees of the Company 119 |
| Class and number of shares to be issued upon the exercise of the stock options | Common stock 115,000 shares | Common stock 375,000 shares |
| Grant date | April 24, 2020 | April 24, 2020 |
| Vesting conditions | No specific conditions are prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted, except for certain vesting conditions stipulated in the exercise conditions. The exercise conditions are described in *(1), (3), (4), (7), and (8). | Same as on the left |
| Vesting period | The period that fulfills the requirement of the exercise condition *(7). | Same as on the left |
| Exercise period | From March 27, 2023 to March 26, 2030 | From March 27, 2023 to March 26, 2030 |

*(1) Fractions less than one unit of a share acquisition right shall be unexercisable.

(2) The Person Granted may exercise all or part of the rights in accordance with the following classifications:

The 26th and the 27th warrants

- (a) Those who were granted the share acquisition rights may exercise the rights within the limit of one-fourth (1/4) from April 18, 2014 to April 17, 2015.
- (b) Those who were granted the share acquisition rights may exercise the rights within the limit of one-half (1/2) from April 18, 2015 to April 17, 2016.
- (c) Those who were granted the share acquisition rights may exercise the rights within the limit of three-fourths (3/4) from April 18, 2016 to April 17, 2017.
- (d) Those who were granted the share acquisition rights may exercise all the rights from April 18, 2017 to April 17, 2022.

The 30th and the 31st warrants

- (a) Those who were granted the share acquisition rights may exercise the rights within the limit of one-fourth (1/4) from May 15, 2015 to May 14, 2016.
 - (b) Those who were granted the share acquisition rights may exercise the rights within the limit of one-half (1/2) from May 15, 2016 to May 14, 2017.
 - (c) Those who were granted the share acquisition rights may exercise the rights within the limit of three-fourths (3/4) from May 15, 2017 to May 14, 2018.
 - (d) Those who were granted the share acquisition rights may exercise all the rights from May 15, 2018 to May 14, 2023.
- (3) The Person Granted shall exercise the rights starting from the date of resolution by the below-mentioned shareholders' meeting or the Board of Directors' meeting until one day before the effective date of the Organizational Restructuring as followed, regardless of the conditions of the exercise period originally stipulated, when the Organizational Restructuring is approved by the resolution of the Company's shareholders' meeting (including the case where resolution of a shareholders' meeting is deemed to exist pursuant to the provision of Article 319 of the Companies Act) or the Board of Directors' meeting (limited to the case where no shareholders' meeting is required for the said Organizational Restructuring) before the exercise period of the share acquisition rights comes into effect: an absorption-type merger or an incorporation-type merger where the Company becomes a dissolving company and an absorption-type split or an incorporation-type company split where the Company becomes a split company, or a share exchange or a share transfer where the Company becomes a wholly-owned subsidiary (collectively, "Organizational Restructuring" as mentioned above).
- (4) The share acquisition rights shall not be offered for pledge or disposed of in any other way.
- (5) A person to whom these stock options are granted ("Person Granted") must have the status as the Company's director, Audit & Supervisory Board member, or employee of the Company or its affiliates at the time of exercise. However, this is not necessarily the case where:
- (a) The Person Granted is a director or Audit & Supervisory Board member of the Company or its affiliates and retires due to the expiry of her/his term.
 - (b) The Person Granted is an employee of the Company or its affiliates and retires due to compulsory retirement.
 - (c) The Person Granted is a director, Audit & Supervisory Board member, or employee of the Company or its affiliates and the Board of Directors resolves that he/she has resigned or retired with honorable recognition.
- (6) In the event that:
- (a) The Person Granted dies before the exercise period comes into effect, the beneficiary/ies shall exercise the rights of up to one-half (1/2) within six (6) months from the date of inheritance, or
 - (b) The Person Granted dies during the exercise period, the beneficiary/ies shall exercise all the rights within six (6) months from the date of inheritance. However, in the event that the beneficiary/ies dies, the rights shall be discarded and shall not be exercised by his/her beneficiary/ies.
- (7) The Person Granted must have the status as a director or employee of the Company or its affiliates at the time of exercise. However, this is not necessarily the case where:
- (a) The Person Granted is a director of the Company or its affiliates and retires due to the expiry of her/his term.
 - (b) The Person Granted is an employee of the Company or its affiliates and retires due to compulsory retirement.
 - (c) The Person Granted is a director or employee of the Company or its affiliates and the Board of Directors resolves that he/she has resigned or retired with honorable recognition.
- (8) In the event that the Person Granted dies, the beneficiary/ies shall be able to succeed and exercise the share acquisition rights as prescribed in the allotment agreement for share acquisition rights entered into between the Company and the Person Granted. However, in the event that the beneficiary/ies dies, the rights shall be discarded and shall not be exercised by his/her beneficiary/ies.

(2) Changes in the size of stock options

(a) Number of stock options

(Unit: number of shares)

| | The 20th Warrant | The 21st Warrant | The 22nd Warrant | The 23rd Warrant |
|------------------------------|------------------|------------------|------------------|------------------|
| Grant date | March 31, 2010 | March 31, 2010 | March 31, 2010 | October 15, 2010 |
| Non-vested shares: | | | | |
| At the beginning of the year | — | — | — | — |
| Granted | — | — | — | — |
| Expired | — | — | — | — |
| Vested | — | — | — | — |
| At the end of the year | — | — | — | — |
| Vested shares: | | | | |
| At the beginning of the year | 86,125 | 32,625 | 38,250 | 2,500 |
| Vested | — | — | — | — |
| Exercised | — | — | — | — |
| Expired | 86,125 | 32,625 | 38,250 | 2,500 |
| At the end of the year | — | — | — | — |

(Unit: number of shares)

| | The 24th Warrant | The 25th Warrant | The 26th Warrant | The 27th Warrant |
|------------------------------|------------------|------------------|------------------|------------------|
| Grant date | March 31, 2011 | March 31, 2011 | May 2, 2012 | May 2, 2012 |
| Non-vested shares: | | | | |
| At the beginning of the year | — | — | — | — |
| Granted | — | — | — | — |
| Expired | — | — | — | — |
| Vested | — | — | — | — |
| At the end of the year | — | — | — | — |
| Vested shares: | | | | |
| At the beginning of the year | 48,000 | 20,500 | 90,625 | 46,200 |
| Vested | — | — | — | — |
| Exercised | — | — | — | — |
| Expired | — | 1,375 | — | 2,825 |
| At the end of the year | 48,000 | 19,125 | 90,625 | 43,375 |

(Unit: number of shares)

| | The 30th Warrant | The 31st Warrant | The 32nd Warrant | The 33rd Warrant |
|------------------------------|------------------|------------------|------------------|------------------|
| Grant date | May 29, 2013 | May 29, 2013 | April 30, 2014 | April 30, 2014 |
| Non-vested shares: | | | | |
| At the beginning of the year | — | — | — | — |
| Granted | — | — | — | — |
| Expired | — | — | — | — |
| Vested | — | — | — | — |
| At the end of the year | — | — | — | — |
| Vested shares: | | | | |
| At the beginning of the year | 29,000 | 12,800 | 17,250 | 20,750 |
| Vested | — | — | — | — |
| Exercised | — | — | — | 5,575 |
| Expired | — | 875 | — | — |
| At the end of the year | 29,000 | 11,925 | 17,250 | 15,175 |

(Unit: number of shares)

| | The 35th Warrant | The 36th Warrant | The 37th Warrant | The 38th Warrant |
|------------------------------|------------------|------------------|------------------|------------------|
| Grant date | April 10, 2015 | April 10, 2015 | April 14, 2016 | April 14, 2016 |
| Non-vested shares: | | | | |
| At the beginning of the year | — | — | — | — |
| Granted | — | — | — | — |
| Expired | — | — | — | — |
| Vested | — | — | — | — |
| At the end of the year | — | — | — | — |
| Vested shares: | | | | |
| At the beginning of the year | 14,050 | 26,875 | 55,000 | 50,400 |
| Vested | — | — | — | — |
| Exercised | — | 6,375 | 37,250 | 19,075 |
| Expired | — | — | — | 50 |
| At the end of the year | 14,050 | 20,500 | 17,750 | 31,325 |

(Unit: number of shares)

| | The 40th Warrant | The 41st Warrant | The 43rd Warrant | The 44th Warrant |
|------------------------------|------------------|------------------|------------------|------------------|
| Grant date | April 24, 2017 | April 24, 2017 | April 26, 2018 | April 26, 2018 |
| Non-vested shares: | | | | |
| At the beginning of the year | 36,250 | 59,050 | 42,500 | 78,325 |
| Granted | — | — | — | — |
| Expired | — | 500 | — | 9,500 |
| Vested | 36,250 | 58,550 | — | 6,500 |
| At the end of the year | — | — | 42,500 | 62,325 |
| Vested shares: | | | | |
| At the beginning of the year | 33,750 | 6,500 | 33,750 | 7,500 |
| Vested | 36,250 | 58,550 | — | 6,500 |
| Exercised | 5,000 | 22,250 | — | — |
| Expired | — | — | — | — |
| At the end of the year | 65,000 | 42,800 | 33,750 | 14,000 |

(Unit: number of shares)

| | The 48th Warrant | The 49th Warrant | The 52nd Warrant | The 53rd Warrant |
|------------------------------|------------------|------------------|------------------|------------------|
| Grant date | April 22, 2019 | April 22, 2019 | April 24, 2020 | April 24, 2020 |
| Non-vested shares: | | | | |
| At the beginning of the year | 73,750 | 154,625 | — | — |
| Granted | — | — | 115,000 | 375,000 |
| Expired | 20,000 | 30,000 | — | 77,250 |
| Vested | 6,250 | 2,250 | — | — |
| At the end of the year | 47,500 | 122,375 | 115,000 | 297,750 |
| Vested shares: | | | | |
| At the beginning of the year | — | — | — | — |
| Vested | 6,250 | 2,250 | — | — |
| Exercised | — | — | — | — |
| Expired | — | — | — | — |
| At the end of the year | 6,250 | 2,250 | — | — |

(b) Per share prices

| | The 20th Warrant | The 21st Warrant | The 22nd Warrant | The 23rd Warrant |
|---|------------------|------------------|------------------|------------------|
| Grant date | March 31, 2010 | March 31, 2010 | March 31, 2010 | October 15, 2010 |
| Exercise price (yen) (Note 1) | 2,340 | 2,340 | 2,340 | 2,340 |
| Average stock price at the time of exercise (yen) | — | — | — | — |
| Fair value price at grant date (yen) | 0 | 0 | 0 | 0 |

| | The 24th Warrant | The 25th Warrant | The 26th Warrant | The 27th Warrant |
|---|------------------|------------------|--|--|
| Grant date | March 31, 2011 | March 31, 2011 | May 2, 2012 | May 2, 2012 |
| Exercise price (yen) (Note 1) | 2,728 | 2,728 | 2,220 | 2,220 |
| Average stock price at the time of exercise (yen) | — | — | — | — |
| Fair value price at grant date (yen) (Note 2) | 0 | 0 | (a) 716 (b) 748 (c) 780 (d) 808 | (a) 716 (b) 748 (c) 780 (d) 808 |

| | The 30th Warrant | The 31st Warrant | The 32nd Warrant | The 33rd Warrant |
|---|--|--|------------------|------------------|
| Grant date | May 29, 2013 | May 29, 2013 | April 30, 2014 | April 30, 2014 |
| Exercise price (yen) (Note 1) | 3,196 | 3,196 | 1 | 1 |
| Average stock price at the time of exercise (yen) | — | — | — | 430 |
| Fair value price at grant date (yen) (Note 2) | (a) 2,344 (b) 2,408 (c) 2,468 (d) 2,524 | (a) 2,344 (b) 2,408 (c) 2,468 (d) 2,524 | 916 | 916 |

| | The 35th Warrant | The 36th Warrant | The 37th Warrant | The 38th Warrant |
|---|------------------|------------------|------------------|------------------|
| Grant date | April 10, 2015 | April 10, 2015 | April 14, 2016 | April 14, 2016 |
| Exercise price (yen) | 1 | 1 | 1 | 1 |
| Average stock price at the time of exercise (yen) | — | 417 | 302 | 379 |
| Fair value price at grant date (yen) | 1,224 | 1,224 | 1,088 | 1,088 |

| | The 40th Warrant | The 41st Warrant | The 43rd Warrant | The 44th Warrant |
|---|------------------|------------------|------------------|------------------|
| Grant date | April 24, 2017 | April 24, 2017 | April 26, 2018 | April 26, 2018 |
| Exercise price (yen) | 1 | 1 | 1 | 1 |
| Average stock price at the time of exercise (yen) | 460 | 429 | — | — |
| Fair value price at grant date (yen) | 812 | 812 | 792 | 792 |

| | The 48th Warrant | The 49th Warrant | The 52nd Warrant | The 53rd Warrant |
|---|------------------|------------------|------------------|------------------|
| Grant date | April 22, 2019 | April 22, 2019 | April 24, 2020 | April 24, 2020 |
| Exercise price (yen) | 1 | 1 | 1 | 1 |
| Average stock price at the time of exercise (yen) | — | — | — | — |
| Fair value price at grant date (yen) | 776 | 776 | 324 | 324 |

(Notes) 1. The Company increased its capital through the public offering on December 4, 2013 and through the third-party allotment on December 25, 2013, at the per share amount less than the exercise price of options. Thus, the exercise amounts above are stated after applying the price adjustments clause.

2. (a), (b), (c), and (d) above correspond to each of (a), (b), (c), and (d) of the exercise periods as previously described in 3. (1) *(2).

4. Method for estimating the fair value of the stock options

The fair value of the stock options that were granted during this fiscal year is estimated based on the following method:

(1) Estimate technique used: Black-Scholes Option Pricing Model

(2) Major assumptions and estimate method

| | The 52nd Warrant | The 53rd Warrant |
|--|------------------|------------------|
| Volatility of stock price ^(Note 1) | 61.56% | 61.56% |
| Estimated remaining period ^(Note 2) | 2.92 years | 2.92 years |
| Estimated dividend ^(Note 3) | 0 yen per share | 0 yen per share |
| Risk-free interest rate ^(Note 4) | (0.154)% | (0.154)% |

(Notes) 1. The volatility was calculated based on the actual stock prices from May 23, 2017 to April 24, 2020.

2. The period from the allotment date to the start date of the exercise period is used.

3. The Company estimates dividends to be zero since no dividends have been paid in the past.

4. This represents yields of Japanese government bonds corresponding to the estimated remaining outstanding period.

5. Estimate of the number of stock options vested

The number of expired shares is estimated based on the historical turnover ratio.

(Asset retirement obligations)

The Company has future restoration obligations related to leasehold contracts for office premises. Carrying the balance of lease and guarantee deposits as an asset, the Company reasonably estimates non-recoverable amounts of lease and guarantee deposits under lease contracts and records the amount attributable to the respective fiscal year as expenses, instead of accounting for asset retirement obligations by recognizing a liability and an associated asset.

(Segment information)

[Segment information]

FY 2019 (from January 1, 2019 to December 31, 2019) and FY 2020 (from January 1, 2020 to December 31, 2020)

Segment information is omitted since the Company operates within a single segment, which includes the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities.

[Related information]

FY 2019 (from January 1, 2019 to December 31, 2019)

1. Information by product and service

Information by product and service is omitted since external sales of a single service category account for more than 90% of net sales stated in the statement of income.

2. Information about geographical areas

(1) Net sales

Net sales information about geographical areas is omitted since external sales to Japanese customers account for more than 90% of net sales stated in the statement of income.

(2) Property, plant and equipment

None to be reported as all property, plant and equipment are located in Japan.

3. Information by the major customer

(Unit: thousands of yen)

| Name of customer | Net sales | Name of related segment |
|------------------|-----------|---|
| Eisai Co., Ltd. | 2,831,272 | Pharmaceutical businesses including the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities |

FY 2020 (from January 1, 2020 to December 31, 2020)

1. Information by product and service

Information by product and service is omitted since external sales of a single service category account for more than 90% of net sales stated in the statement of income.

2. Information about geographical areas

(1) Net sales

Net sales information about geographical areas is omitted since external sales to Japanese customers account for more than 90% of net sales stated in the statement of income.

(2) Property, plant and equipment

None to be reported as all property, plant and equipment are located in Japan.

3. Information by the major customer

(Unit: thousands of yen)

| Name of customer | Net sales | Name of related segment |
|------------------------------|-----------|---|
| Eisai Co., Ltd. | 2,545,650 | Pharmaceutical businesses including the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities |
| SUZUKEN CO., LTD. | 125,526 | Pharmaceutical businesses including the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities |
| TOHO PHARMACEUTICAL CO., LTD | 119,510 | Pharmaceutical businesses including the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities |

[Information about impairment loss on non-current assets by reportable segment]

FY 2019 (from January 1, 2019 to December 31, 2019) and FY 2020 (from January 1, 2020 to December 31, 2020)
None to be reported.

[Information about the amortization and unamortized balance of goodwill by reportable segment]

FY 2019 (from January 1, 2019 to December 31, 2019) and FY 2020 (from January 1, 2020 to December 31, 2020)
None to be reported.

[Information about the gain on bargain purchase by reportable segment]

FY 2019 (from January 1, 2019 to December 31, 2019) and FY 2020 (from January 1, 2020 to December 31, 2020)
None to be reported.

(Affiliated party information)

Transactions with affiliated parties

Officer(s) and major individual shareholder(s) of the Company

FY 2019 (from January 1, 2019 to December 31, 2019)

None to be reported.

FY 2020 (from January 1, 2020 to December 31, 2020)

| Category | Name of company or person | Location | Capital or investment (thousands of yen) | Business details or profession | Ratio of voting rights and other forms of ownership (ownership) (%) | Relationships with affiliated parties | Transaction details | Transaction amount (thousands of yen) | Account title | Year-end balance (thousands of yen) |
|-----------|---------------------------|----------|--|---|---|---------------------------------------|--------------------------------------|---------------------------------------|---------------|-------------------------------------|
| Executive | Fuminori Yoshida | — | — | Representative Director, President and Chief Executive Officer of the Company | (Ownership) Direct: 2.40 | — | Exercise of share acquisition rights | 40,565 (37,250 shares) | — | — |

(Note) This information describes the exercise during the fiscal year under review of share acquisition rights granted based on resolutions at Board of Directors meetings on March 30, 2016.

(Per share information)

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|----------------------|---|---|
| Net assets per share | 143.07 yen | 105.76 yen |
| Loss per share | (189.03) yen | (124.13) yen |

(Notes) 1. While having potential dilutive shares, diluted earnings per share is not provided since the Company reported loss per share.

2. The Company conducted a 1-for-4 consolidation of common shares on July 1, 2019. Net assets per share and loss per share have been calculated based on the assumption that this consolidation was conducted at the beginning of FY 2018.

3. The basis for calculating loss per share is as follows:

| | FY 2019 (from January 1, 2019 to December 31, 2019) | FY 2020 (from January 1, 2020 to December 31, 2020) |
|---|---|---|
| Loss (thousands of yen) | (4,376,258) | (4,090,216) |
| Amount not attributable to the shareholders of common stock (thousands of yen) | — | — |
| Loss attributable to the shareholders of common stock (thousands of yen) | (4,376,258) | (4,090,216) |
| Average number of shares outstanding during the year (shares) | 23,150,655 | 32,950,201 |
| Description of potential dilutive shares not included in the earning-per-share calculation due to anti-dilution | 23 types of share acquisition rights (2,791,950 units) in accordance with the Commercial Code of 1890 Article 280 (20) and (21), and the Companies Act Article 236, 238, and 239. | 23 types of share acquisition rights (1,209,600 units) in accordance with the Commercial Code of 1890 Article 280 (20) and (21), and the Companies Act Article 236, 238, and 239. |

4. The basis for calculating net assets per share is as follows:

| | FY 2019 (as of December 31, 2019) | FY 2020 (as of December 31, 2020) |
|--|--------------------------------------|--------------------------------------|
| Net assets (thousands of yen) | 4,400,116 | 4,657,318 |
| Amount to be deducted from net assets (thousands of yen) | 620,913 | 620,140 |
| (Of which, share acquisition rights herein [thousands of yen]) | (620,913) | (620,140) |
| Net assets attributable to the shareholders of common stock (thousands of yen) | 3,779,202 | 4,037,177 |
| Number of shares used in the calculation of net assets per share (shares) | 26,415,088 | 38,172,813 |

(Significant subsequent events)

None to be reported.

6. Other

(1) Change in officers

For information regarding change in officers, see the “Notice of Appointment of Corporate Officer” released on December 23, 2020.

(2) Other

None to be reported.